naltrexone and acamprosate

naltrexone has been researched along with acamprosate in 270 studies

Research

Studies (270)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's17 (6.30)18.2507
2000's115 (42.59)29.6817
2010's105 (38.89)24.3611
2020's33 (12.22)2.80

Authors

AuthorsStudies
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Schuckit, MA1
Litten, RZ1
Overstreet, DH1
Spanagel, R; Zieglgänsberger, W1
Swift, RM1
Drummond, DC; Moncrieff, J1
Allen, JP; Litten, RZ2
Gache, P; Siegrist, G1
Bonn, D1
Carey, TS; Crews, FT; Garbutt, JC; Lohr, KN; West, SL1
Malerich, JA1
Rueff, B1
Mason, B1
Farren, CK; O'Malley, SS1
Cole, JC; Little, HJ; Littleton, JM1
Fiellin, DA; O'Connor, PG; Reid, MC1
Ait-Daoud, N; Johnson, BA1
Hölter, SM; Spanagel, R1
Koob, GF1
Kalb, C1
Brady, KT; Malcolm, R; Myrick, H1
Mackler, SA; O'Brien, CP; Stromberg, MF; Volpicelli, JR1
Boening, JA; Lesch, OM; Mason, BJ; Narita, M; Sinclair, D; Spanagel, R; Wiesbeck, GA; Wolffgramm, J1
Tedeschi, M1
Bean, P; Mattson, M1
Carey, TS; Crews, FT; Garbutt, JC; Jackman, AM; Lohr, KN; Lux, LJ; Tolleson-Rinehart, S; West, SL1
Gordon, SM1
Korpi, E; Seppälä, T1
Kranzler, HR; Van Kirk, J1
Anton, RF1
Yarborough, WH1
Fideli, LP; Lejoyeux, M1
Graham, R; Whelan, G; Wodak, AD1
Boyeson, MG; Dixon, RM; Goodman, AM; Hameed, MH; Hulot, T; Hunter, JA; Mason, BJ; Wesnes, K1
Baehr, M; Briken, P; Helwig, H; Holzbach, R; Jahn, H; Kämpf, P; Kiefer, F; Naber, D; Stracke, R; Tarnaske, T; Wiedemann, K1
Mason, BJ3
Heyser, CJ; Koob, GF; Moc, K1
Bransberger, P; Crosse, S; Kranzler, HR; Mark, TL; Poole, VH; Song, X1
Chambers, RA; Ciraulo, DA; Couper, D; Johnson, BA; O'Malley, SS; Roache, JD; Sarid-Segal, O1
O'Brien, CP3
Doran, CM; Fawcett, JE; Mattick, RP; Shakeshaft, AP; Shanahan, MD1
Han, BD; Kim, MJ; Kim, SG; Park, JM; Stromberg, MF1
Salaspuro, M1
Littleton, J; Zieglgänsberger, W1
Anton, RF; Swift, RM1
Chick, J; Soyka, M1
Amate, JM; Angeles, M; Bouza, C; Magro, A; Muñoz, A1
Bespalov, A; Danysz, W; Kashkin, V; Malyshkin, A; Neznanova, O; Sukhotina, I; Zakharova, E1
Anton, R; Myrick, H1
Lee, TH1
Kenna, GA; McGeary, JE; Swift, RM1
Baltieri, DA; Castro, LA1
Helwig, H; Jahn, H; Kiefer, F; Otte, C; Tarnaske, T; Wiedemann, K1
Demiralay, C; Jahn, H; Kiefer, F; Otte, C; Wiedemann, K; Wolf, K1
Jahn, H; Kiefer, F; Wiedemann, K1
Berglund, M; Johnson, BA; Lesch, OM; Litten, RZ; Mann, K; Swift, RM; Willenbring, ML1
Litten, RZ; Mattson, ME1
Anton, R; Goldman, D; O'Malley, S; Oroszi, G1
Pettinati, HM; Swift, R1
Ait-Daoud, N; Johnson, BA; Roache, JD1
Buonopane, A; Petrakis, IL1
Williams, SH1
Egli, M1
Sher, L1
Jahn, H; Kiefer, F; Naber, D; Otte, C; Wiedemann, K1
Beilby, JJ; Doran, CM; Duszynski, KM; Mattick, RP1
Egli, M; Heilig, M1
Jung, YC; Namkoong, K1
Anton, RF; Ciraulo, DA; Cisler, RA; Couper, D; Donovan, DM; Gastfriend, DR; Hosking, JD; Johnson, BA; LoCastro, JS; Longabaugh, R; Mason, BJ; Mattson, ME; Miller, WR; O'Malley, SS; Pettinati, HM; Randall, CL; Swift, R; Weiss, RD; Williams, LD; Zweben, A1
Leeman, RF; Starosta, AN; Volpicelli, JR1
Escher, T; Mittleman, G1
Balester-Mouret, S; Batel, P1
Bell, JR; Haber, PS; Morley, KC; Phung, N; Reid, SC; Richardson, K; Sannibale, C; Teesson, M; Thomson, C; Weltman, M1
Pettinati, HM; Rabinowitz, AR1
Kranzler, HR2
Doggrell, SA1
Bleich, S; Hillemacher, T; Kornhuber, J1
Roesner, S; Soyka, M1
Ducharme, LJ; Knudsen, HK; Roman, PM1
Diehl, A; Mann, K1
Mørland, J1
Baer, JS; Forcehimes, AA; Kenna, GA; Miller, WR; Tonigan, JS1
Quertemont, E; Tambour, S1
Bray, JW; Cisler, RA; Couper, DJ; Kivlahan, DR; Martin, DJ; Miller, WR; Mitra, D; Zarkin, GA1
Swift, R1
Peterson, AM1
McDonough, KP1
Brunette, MF; Drake, RE; Green, AI; Noordsy, DL1
Koeter, MW; Ooteman, W; Schippers, GM; van den Brink, W; Verheul, R1
Andreoli, M; Ashby, CR; Gardner, EL; Heidbreder, CA; Hutcheson, DM; Marcon, C1
Diehl, A; Jiménez-Arriero, MA; Kiefer, F; Klein, O; Rubio, G1
Brunette, MF; Green, AI; Noordsy, DL; O'Keefe, C1
Johnson, BA1
Kuehn, BM1
Lehert, P; Leucht, S; Rösner, S; Soyka, M1
Anton, RF; Couper, D; Goldman, D; O'Malley, S; Oroszi, G; Pettinati, H; Swift, R1
Burattini, C; Gass, JT; Griffin, WC; Janak, PH; Kinder, JR; McGeehan, AJ; Olive, MF1
Berglund, M; Gorelick, D; Hesselbrock, V; Johnson, BA; Kranzler, HR; Möller, HJ; Soyka, M1
Blanc, F; Perney, P; Rigole, H1
Shea, CW1
Giménez-Llort, L; Guitart-Masip, M; Hassankhali, H; Johansson, B; Landgren, S; Lindholm, J; Nicoleau, C; Ogren, SO; Terenius, L1
Baillie, A; Haber, P; Morley, K; Reid, S; Richardson, K; Sannibale, C; Teesson, M; Weltman, M1
Bowers, TG; Snyder, JL1
Ciraulo, D; Cox, CE; Gorroochurn, P; Mattson, ME; Pettinati, HM; Weiss, RD; Youngblood, M; Zweben, A1
Abernathy, KE; Bartlett, SE; Chandler, LJ; Medina, B; Simms, JA; Steensland, P; Wise, R1
Soyka, M1
Kassed, CA; Kranzler, HR; Levit, KR; Mark, TL; Vandivort-Warren, R1
Aldridge, A; Bray, JW; Cisler, RA; Couper, DJ; Mills, MJ; Mitra, D; Zarkin, GA1
Hosking, JD; Locastro, JS; O'malley, SS; Swift, R; Weiss, RD1
Garbutt, JC1
Diehl, A; Herre, H; Kiefer, F; Mann, K; Mutschler, J; Vollmert, C1
Czachowski, CL; Delory, MJ1
Gann, H; Heinz, A; Kiefer, F; Mann, K; Smolka, M; Wellek, S1
Boakes, R; Colagiuri, B; Haber, P; Morley, K1
Kenna, GA; Leggio, L; Ray, LA; Swift, RM1
Daoust, M; Houchi, H; Koeter, MW; Naassila, M; Ooteman, W; Schippers, GM; van den Brink, W; Verheul, R1
Rösner, S; Soyka, M2
de Silva, V; Hanwella, R1
Oslin, DW; Ray, LA1
Couper, D; Donovan, D; Gueorguieva, R; Krystal, JH; O'Malley, SS; Rounsaville, BJ; Wu, R3
Abraham, AJ; Knudsen, HK; Roman, PM; Rothrauff, TC1
Olive, MF1
Bray, JW; Dunlap, LJ; Kivlahan, DR; Latham, P; McKay, JR; Mills, M; Tonigan, JS; Zarkin, GA1
Bowe, T; Harris, AH; Humphreys, KN; Kivlahan, DR1
Aldridge, A; Bray, JW; Cisler, RA; Couper, D; McKay, JR; Mills, M; O'Malley, S; Zarkin, GA1
Grosshans, M; Kiefer, F; Kobiella, A; Mutschler, J1
Greenfield, SF; O'Malley, S; Pettinati, HM; Randall, CL; Randall, PK1
Falk, D; Fertig, J; Johnson, B; Litten, RZ; Liu, L; Mattson, M; Ryan, M; Stout, R; Wang, XQ1
Longabaugh, R; O'Malley, SS; Wirtz, PW; Zywiak, WH1
Capone, C; Kahler, CW; O'Malley, SS; Swift, RM1
Bowen, S; Donovan, DM; Witkiewitz, K1
Chalk, M; Gastfriend, DR; Kranzler, HR; Mark, TL; Montejano, LB1
Alam, DA; Martorana, A1
Abraham, AJ; Knudsen, HK; Roman, PM1
Donovan, D; Hartzler, B; Villarroel, N; Witkiewitz, K1
Baser, O; Chalk, M; Gastfriend, DR; Rawson, R1
Campanella, S; Kornreich, C; Noel, X; Petit, G; Verbanck, P1
Godinho, A; Mohapatra, S; Patra, J; Popova, S; Rehm, J; Schwappach, D1
Lumbad, J; Yancey, JR1
Krogh, J; Nordentoft, M; Petrov, I1
Bujarski, S; Courtney, KE; Ray, LA; Squeglia, LM1
Hunter-Reel, D; Witkiewitz, K; Zweben, A1
Doran, CM; Navarro, HJ; Petrie, DJ; Shakeshaft, A1
Spanagel, R; Vengeliene, V1
Book, SW; Miller, PM; Stewart, SH1
Chen, J; Isaac, M; Johnson, BA; Liu, L; O'Quigley, J; Wang, XQ; Zhang, D1
Fucito, LM; Gueorguieva, RV; Gulliver, SB; Mattson, ME; O'Malley, SS; Park, A1
Bandyopadhyay, D; DeSantis, SM; Prisciandaro, JJ1
Clark, DB1
Bühler, KM; Echeverry-Alzate, V; Giné, E; Gorriti, MÁ; Huertas, E; López-Moreno, JA; Olmos, P; Rodríguez de Fonseca, F; Santos, Á; Tuda-Arízcun, M1
Gahr, M; Kölle, MA; Schönfeldt-Lecuona, C1
Blodgett, JC; Finney, JW; Humphreys, K; Maisel, NC; Wilbourne, PL1
Anton, RF; Batra, A; Berner, M; Heinz, A; Hermann, D; Hoffmann, S; Kiefer, F; Lemenager, T; Mann, K; Reinhard, I; Smolka, MN; Wellek, S; Wodarz, N; Zimmermann, US1
Bujarski, S; Lunny, K; O'Malley, SS; Ray, LA1
Bowe, T; Ellerbe, L; Gordon, AJ; Hagedorn, H; Harris, AHS; Kivlahan, D; Lembke, A; Oliva, E; Reeder, RN; Trafton, JA1
Choi, IG; Kang, TC; Kim, JW; Lee, BC1
Donovan, D; Gueorguieva, R; Krystal, JH; O'Malley, SS; Wu, R1
Anton, RF; Baker, NL; Bandyopadhyay, D; DeSantis, SM; Prisciandaro, JJ; Randall, PK1
O'Connor, PG; O'Malley, SS1
Krishnan-Sarin, S; Krystal, JH; O'Malley, S1
Franck, J; Jayaram-Lindström, N1
Falk, D; Fertig, J; Litten, RZ; Ryan, M1
Castle, IJ; Chen, CM; Falk, D; Fertig, J; Litten, RZ; Ryan, M; Yi, HY1
Heinz, A; Müller, CA1
Amick, HR; Bobashev, G; Feltner, C; Garbutt, JC; Gass, CE; Jonas, DE; Kim, MM; Rowe, CJ; Shanahan, E; Thomas, K; Wines, R1
DeSantis, SM; Zhu, H1
Liang, J; Olsen, RW1
Braciszewski, JM; Falk, D; Kranzler, HR; O'Malley, SS; Stout, RL; Subbaraman, MS1
Friedmann, PD; Park, TW1
Oetzel, S1
Anton, RF; Book, SW; Schacht, JP1
Goutier, W; Kloeze, M; McCreary, AC1
Fucito, LM; Gueorguieva, R; Hoffmann, S; Mann, K; O'Connor, PG; O'Malley, SS; Weisner, C; Wu, R1
Borro, P; Leone, S; Testino, G1
Amato, RJ; Hulin, MW; Lawrence, MN; Weed, PF; Winsauer, PJ1
Donoghue, K; Drummond, C; Elzerbi, C; Pilling, S; Saunders, R; Whittington, C1
Saitz, R1
Lieb, M; Soyka, M1
Frohe, T; Kirouac, M; Maisto, SA; McCallion, E; Vowles, KE; Witkiewitz, K1
Chalk, M; Lubran, R; Mark, TL; McCance-Katz, EF; Richardson, J1
Agabio, R; Franconi, F; Gessa, GL; Pani, PP; Preti, A1
Gofman, AG; Ponizovskiy, PA1
Higuchi, S; Yumoto, Y1
Helton, SG; Lohoff, FW1
Anton, RF; Fitzmaurice, GM; Griffin, ML; McHugh, RK; Weiss, RD1
Houck, J; Longabaugh, R; Miller, WR; Moyers, TB; Rice, SL1
Creedon, TB; Hodgkin, D; Horgan, CM; Matteucci, AM; Reif, S; Stewart, MT1
Cicin-Šain, L; Kovak-Mufić, A; Marušić, S; Matošić, A; Vidrih, B1
Baillie, A; Haber, PS; Logge, W; Morley, KC; Pearson, SA2
Salisbury-Afshar, E1
Bramness, JG; Mann, K; Wurst, FM1
Mann, K; Roos, CR; Witkiewitz, K1
Bowe, T; Christopher, M; Finlay, AK; Gidwani, R; Hagedorn, H; Harris, AH; Kay, C; Nevedal, A; Rosen, C1
Crits-Christoph, P; Gallop, R; Gastfriend, DR; Gibbons, MB; Lundy, C; Markell, HM; Stringer, M1
Metrik, J; Patterson, D; Subbaraman, MS; Swift, R1
Brewer, C; Skinner, M; Streel, E1
Goh, ET; Morgan, MY1
Manolopoulos, VG; Ragia, G1
Bowe, TR; Burden, JL; Ellerbe, LS; Finlay, AK; Gupta, S; Harris, AHS; Rubinsky, AD; Timko, C; Wong, JJ1
Gomes, T; Martins, D; Singh, S; Spithoff, S; Turner, S1
Hallgren, KA; Heather, N; Kirouac, M; Maisto, SA; Montes, KS; Pearson, MR; Roos, CR; Wilson, AD; Witkiewitz, K1
Lyon, J1
Barkley-Levenson, A; Crabbe, JC; Hack, WR; Huang, LC; Metten, P; Ozburn, AR; Schlumbohm, JP; Spence, SE1
Ericson, M; Lidö, HH; Söderpalm, B1
Boussageon, R; Duprez, R; Huneau, A; Laviolle, B; Locher, C; Naudet, F; Palpacuer, C1
Bonnet, U; Dembski, N; Niederhofer, A; Niederhofer, E; Nyhuis, PW; Scherbaum, N; Schifano, F; Specka, M; Tenbergen, M1
Heinz, A; Hoffmann, S; Leménager, T; Mann, K; Nakovics, H; Roos, CR; Witkiewitz, K1
Falk, DE; Fertig, J; Leggio, L; Litten, RZ; Ryan, ML2
Donoghue, K1
Diouf, M; González-Marín, MC; Jeanblanc, J; Lebourgeois, S; Naassila, M1
Hughes, JR; Klemperer, EM; Naud, S1
Binswanger, IA; Fazel, S; Hellner, C; Larsson, H; Molero, Y; Zetterqvist, J1
Kranzler, HR; Soyka, M1
Chaignot, C; Coste, J; Dray-Spira, R; Rey, G; Weill, A; Zureik, M1
Bekier, NK; Brünen, S; Hiemke, C; Jahn, H; Kiefer, F; Korf, F; Wiedemann, K1
Coenen, MJH; Kievit, W; Schellekens, A; Schene, AH; Sluiter, RL; Teichert, M; van der Wilt, GJ1
Bramness, JG; Heldal, AT; Lobmaier, PPK; Skurtveit, S; Vederhus, JK1
Harris, AHS; Matson, TE; Williams, EC1
Warren, D1
Alho, H; Castrén, S; Mäkelä, N1
Bonnet, U; Holzbach, R; Kirchof, U; Scherbaum, N; Stammen, G1
Hartwell, KJ; Korte, JE; McRae-Clark, AL; Walker, JR1
Akgün, K; Bryant, K; Crystal, S; Edelman, EJ; Fiellin, DA; Fiellin, LE; Gaither, JR; Gordon, AJ; Goulet, JL; Justice, AC; Korthuis, PT; Kraemer, KL; Marshall, BDL; McGinnis, KA; Oldfield, BJ; Williams, EC1
Hulme, J; Sheikh, H; Wiercigroch, D1
Anton, RF; Falk, DE; Hasin, DS; Heather, N; Kranzler, HR; Litten, RZ; Mann, KF; O'Malley, SS; Witkiewitz, K1
Graziani, R; Venturini, S1
Fairbanks, J; Karpyak, VM; Kolla, BP; Loukianova, LL; Schneekloth, TD; Sinha, S; Umbreit, A1
Kenny, PJ; O'Brien, CP; Pierce, RC; Swinford-Jackson, SE; Unterwald, EM; Vanderschuren, LJMJ1
Hong, TK; Huh, SY; Kim, SG1
Haass-Koffler, CL; Kenna, GA; Lee, MR; Leggio, L; Li, X; Long, VM; Piacentino, D; Swift, RM1
Avanceña, ALV; Hutton, DW; Mellinger, JL; Miller, N; Uttal, SE1
Heikkinen, M; Lähteenvuo, M; Mittendorfer-Rutz, E; Taipale, H; Tanskanen, A; Tiihonen, J1
Balasanova, AA; Patel, AK1
Greenland, M; Kelty, E; Preen, D; Terplan, M1
Ahamad, K; Bach, P; Mong, J1
Heyser, CJ; Mason, BJ1
English, K; Gu, LY; Madden, EF; Mensah, NA; Qeadan, F; Venner, KL1
Worley, J1
Askgaard, G; Nielsen, AS; Thiele, M1
Kranzler, HR; Mann, K; Nakovics, H; Roos, CR; Votaw, VR; Witkiewitz, K1
Burnette, EM; Gillis, AJ; Grodin, EN; Hurley, B; Meredith, LR; Miotto, K; Nieto, SJ; Ray, LA1
Cheong, JC; Kim, JY; Kim, SY; Shin, DW; Suh, S1
Addolorato, G; Antonelli, M; Sestito, L; Tarli, C1
Bain, PA; Busch, AB; Huskamp, HA; Hyland, CJ; McDowell, MJ1
Gomes, T; Konstantelos, N; Lecce, P; McCormack, D; Tadrous, M; Tourchian, N1
Agabio, R; Minozzi, S; Rösner, S; Saulle, R1
Falker, C; Garcia-Tsao, G; Kaplan, DE; Mahmud, N; Rabiee, A; Taddei, T1
Alto, M; Giusto, A; Greene, MC; Johnson, RM; Kane, J; Lovero, K; McClendon, J; Nicholson, T; Stockton, M; Tol, WA; Wainberg, ML1
Conigrave, JH; Conigrave, KM; Lee, KSK; Purcell-Khodr, G; Vnuk, J1
Drexler, K; Hsu, M; Malhotra, A; Tang, YL1
Bobashev, G; Coffey, CP; Edlund, MD; Jonas, DE; Kennedy, SM; Kuznacic, K; McPheeters, M; O'Connor, EA; Riley, S; Voisin, C1

Reviews

110 review(s) available for naltrexone and acamprosate

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
Recent developments in the pharmacotherapy of alcohol dependence.
    Journal of consulting and clinical psychology, 1996, Volume: 64, Issue:4

    Topics: Acamprosate; Alcohol Deterrents; Anti-Anxiety Agents; Buspirone; Disulfiram; Ethanol; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Substance-Related Disorders; Taurine

1996
Anti-craving compounds for ethanol: new pharmacological tools to study addictive processes.
    Trends in pharmacological sciences, 1997, Volume: 18, Issue:2

    Topics: Acamprosate; Alcoholism; Animals; Behavior, Animal; Calcium Channels; Disease Models, Animal; Humans; Naltrexone; Narcotic Antagonists; Neurons; Rats; Receptors, N-Methyl-D-Aspartate; Receptors, Opioid; Recurrence; Substance Withdrawal Syndrome; Synaptic Transmission; Taurine

1997
The pharmacological treatment of alcohol dependence.
    Medicine and health, Rhode Island, 1997, Volume: 80, Issue:3

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Antidepressive Agents; Comorbidity; Depression; Disulfiram; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Serotonin Antagonists; Serotonin Receptor Agonists; Taurine

1997
Advances in development of medications for alcoholism treatment.
    Psychopharmacology, 1998, Volume: 139, Issue:1-2

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Antidepressive Agents; Drug Therapy, Combination; Humans; Naltrexone; Taurine

1998
Medications for alcohol, illicit drug, and tobacco dependence. An update of research findings.
    Journal of substance abuse treatment, 1999, Volume: 16, Issue:2

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Buprenorphine; Bupropion; Forecasting; Humans; Methadyl Acetate; Naltrexone; Substance-Related Disorders; Taurine; Tobacco Use Disorder

1999
Pharmacological treatment of alcohol dependence: a review of the evidence.
    JAMA, 1999, Apr-14, Volume: 281, Issue:14

    Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Disulfiram; Humans; Lithium; Naltrexone; Narcotic Antagonists; Serotonin Agents; Taurine

1999
[Evaluation of drug treatment of primary alcoholism].
    La Revue du praticien, 1999, Feb-15, Volume: 49, Issue:4

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Follow-Up Studies; Humans; Naltrexone; Self-Help Groups; Taurine; Treatment Outcome

1999
New therapies for alcohol problems: application to primary care.
    The American journal of medicine, 2000, Feb-15, Volume: 108, Issue:3

    Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcohol-Related Disorders; Clinical Trials as Topic; Humans; Naltrexone; Narcotic Antagonists; Primary Health Care; Psychotherapy; Research Design; Taurine; United States

2000
Neuropharmacological treatments for alcoholism: scientific basis and clinical findings.
    Psychopharmacology, 2000, Volume: 149, Issue:4

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Drug Therapy, Combination; Humans; Naltrexone; Narcotic Antagonists; Receptors, N-Methyl-D-Aspartate; Serotonin Antagonists; Serotonin Receptor Agonists; Taurine

2000
Animal models of craving for ethanol.
    Addiction (Abingdon, England), 2000, Volume: 95 Suppl 2

    Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Animals; Behavior, Addictive; Conditioning, Operant; Disease Models, Animal; Drug Tolerance; Motivation; Naltrexone; Narcotic Antagonists; Predictive Value of Tests; Rats; Reinforcement, Psychology; Reproducibility of Results; Substance Withdrawal Syndrome; Taurine

2000
New developments in the pharmacotherapy of alcohol dependence.
    The American journal on addictions, 2001, Volume: 10, Issue:s1

    Topics: Acamprosate; Adjuvants, Anesthesia; Alcohol Deterrents; Alcoholism; Anticonvulsants; Buspirone; Carbamazepine; Drug Therapy; Ethanol; Humans; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Ritanserin; Serotonin Agents; Sodium Oxybate; Substance Withdrawal Syndrome; Taurine; Valproic Acid; Vigabatrin

2001
Pharmacological relapse prevention in alcohol dependence: from animal models to clinical trials.
    Alcoholism, clinical and experimental research, 2001, Volume: 25, Issue:5 Suppl IS

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Clinical Trials as Topic; Disease Models, Animal; Dopamine Agents; Humans; Naltrexone; Narcotic Antagonists; Prosencephalon; Rats; Receptors, N-Methyl-D-Aspartate; Secondary Prevention; Serotonin Agents; Taurine

2001
Naltrexone and acamprosate. Using new drugs for alcohol dependence.
    Australian family physician, 2001, Volume: 30, Issue:5

    Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Australia; Clinical Trials as Topic; Female; Guidelines as Topic; Humans; Male; Naltrexone; Narcotic Antagonists; Patient Satisfaction; Prognosis; Taurine; Treatment Outcome

2001
Pharmacotherapy for alcohol dependence.
    Evidence report/technology assessment (Summary), 1999, Issue:3

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Health Policy; Humans; Lithium; Naltrexone; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Serotonin Agents; Taurine; United States

1999
[Alcohol--mechanism of action, interactions and treatment of alcohol abuse].
    Duodecim; laaketieteellinen aikakauskirja, 1998, Volume: 114, Issue:10

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Drug Interactions; Ethanol; Humans; Naltrexone; Narcotic Antagonists; Substance Withdrawal Syndrome; Taurine

1998
Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis.
    Alcoholism, clinical and experimental research, 2001, Volume: 25, Issue:9

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Depression; Female; gamma-Glutamyltransferase; Humans; Male; Naltrexone; Narcotic Antagonists; Placebos; Secondary Prevention; Selective Serotonin Reuptake Inhibitors; Taurine; Treatment Outcome

2001
Pharmacologic approaches to the management of alcoholism.
    The Journal of clinical psychiatry, 2001, Volume: 62 Suppl 20

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Behavior, Addictive; Clinical Trials as Topic; Disulfiram; Humans; Naltrexone; Narcotic Antagonists; Taurine; Treatment Outcome

2001
[Long-term treatment of alcohol dependance].
    Gastroenterologie clinique et biologique, 2002, Volume: 26, Issue:5 Suppl

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Combined Modality Therapy; Disulfiram; Family Therapy; Humans; Long-Term Care; Naltrexone; Psychotherapy; Self-Help Groups; Social Support; Social Work; Taurine; Treatment Outcome

2002
New pharmacotherapies for alcohol dependence.
    The Medical journal of Australia, 2002, Jul-15, Volume: 177, Issue:2

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Australia; Disulfiram; Humans; Naltrexone; Narcotic Antagonists; Self-Help Groups; Taurine; Treatment Outcome

2002
Acamprosate.
    Recent developments in alcoholism : an official publication of the American Medical Society on Alcoholism, the Research Society on Alcoholism, and the National Council on Alcoholism, 2003, Volume: 16

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Double-Blind Method; Humans; Multicenter Studies as Topic; Naltrexone; Randomized Controlled Trials as Topic; Taurine; Treatment Outcome

2003
Research advances in the understanding and treatment of addiction.
    The American journal on addictions, 2003, Volume: 12, Issue:s2

    Topics: Acamprosate; Alcohol Deterrents; Brain; Chronic Disease; Disease Progression; Humans; Naltrexone; Narcotics; Prognosis; Recurrence; Risk Factors; Substance-Related Disorders; Taurine

2003
Acamprosate and naltrexone treatment for alcohol dependence: an evidence-based risk-benefits assessment.
    European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2003, Volume: 13, Issue:6

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Double-Blind Method; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Taurine

2003
[Drug therapy of alcohol dependence--a critical review].
    Duodecim; laaketieteellinen aikakauskirja, 2003, Volume: 119, Issue:24

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Anticonvulsants; Fructose; Humans; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Taurine; Topiramate

2003
Pharmacological mechanisms of naltrexone and acamprosate in the prevention of relapse in alcohol dependence.
    The American journal on addictions, 2003, Volume: 12, Issue:s1

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Behavior, Animal; Brain; Humans; Naltrexone; Narcotic Antagonists; Receptors, Glutamate; Recurrence; Taurine

2003
Current pharmacotherapies of alcoholism: a U.S. perspective.
    The American journal on addictions, 2003, Volume: 12, Issue:s1

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Anticonvulsants; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Naltrexone; Narcotic Antagonists; Receptors, Glutamate; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Serotonin Receptor Agonists; Taurine; United States

2003
Use of acamprosate and opioid antagonists in the treatment of alcohol dependence: a European perspective.
    The American journal on addictions, 2003, Volume: 12, Issue:s1

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Europe; Humans; Meta-Analysis as Topic; Naltrexone; Narcotic Antagonists; Placebos; Randomized Controlled Trials as Topic; Receptors, N-Methyl-D-Aspartate; Taurine; Treatment Outcome

2003
Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review.
    Addiction (Abingdon, England), 2004, Volume: 99, Issue:7

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Humans; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Taurine; Treatment Outcome

2004
Recent advances in the pharmacotherapy of alcoholism.
    Current psychiatry reports, 2004, Volume: 6, Issue:5

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Anticonvulsants; Clinical Trials as Topic; Fructose; Humans; Naltrexone; Narcotic Antagonists; Neurotransmitter Agents; Taurine; Topiramate

2004
Pharmacotherapy, pharmacogenomics, and the future of alcohol dependence treatment, part 1.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2004, Nov-01, Volume: 61, Issue:21

    Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcohol-Related Disorders; Animals; Clinical Trials as Topic; Disulfiram; Excitatory Amino Acid Antagonists; Humans; Naltrexone; Narcotic Antagonists; Taurine

2004
Combining treatments for alcoholism: why and how?
    Journal of studies on alcohol. Supplement, 2005, Issue:15

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Clinical Trials as Topic; Combined Modality Therapy; Humans; Naltrexone; Narcotic Antagonists; Psychotherapy; Taurine

2005
COMBINE genetics study: the pharmacogenetics of alcoholism treatment response: genes and mechanisms.
    Journal of studies on alcohol. Supplement, 2005, Issue:15

    Topics: Acamprosate; Alcohol Dehydrogenase; Alcohol Deterrents; Alcoholism; Alleles; Combined Modality Therapy; Drug Therapy; Genetic Markers; Genotype; Haplotypes; Humans; Naltrexone; Narcotic Antagonists; Polymorphism, Genetic; Psychotherapy; Randomized Controlled Trials as Topic; Receptors, Opioid, mu; Taurine

2005
Rationale for combining acamprosate and naltrexone for treating alcohol dependence.
    Journal of studies on alcohol. Supplement, 2005, Issue:15

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Drug Therapy, Combination; Humans; Naltrexone; Narcotic Antagonists; Taurine

2005
Pharmacotherapy of alcohol use disorders.
    Substance use & misuse, 2005, Volume: 40, Issue:13-14

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Amitriptyline; Antidepressive Agents, Tricyclic; Comorbidity; Disulfiram; Dopamine; Drug Interactions; Ethanol; Female; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Male; Mental Disorders; Naltrexone; Narcotics; Serotonin; Taurine

2005
Medications for treating alcohol dependence.
    American family physician, 2005, Nov-01, Volume: 72, Issue:9

    Topics: Acamprosate; Adult; Aged; Alcohol Deterrents; Alcohol-Related Disorders; Alcoholism; Disulfiram; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Middle Aged; Naltrexone; Patient Compliance; Randomized Controlled Trials as Topic; Serotonin Agents; Taurine; Treatment Outcome

2005
Can experimental paradigms and animal models be used to discover clinically effective medications for alcoholism?
    Addiction biology, 2005, Volume: 10, Issue:4

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Clinical Trials as Topic; Disease Models, Animal; Drug Evaluation, Preclinical; Humans; Naltrexone; Rodentia; Taurine

2005
Alcoholism and suicidal behavior: a clinical overview.
    Acta psychiatrica Scandinavica, 2006, Volume: 113, Issue:1

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Antidepressive Agents, Tricyclic; Anxiety; Comorbidity; Depressive Disorder, Major; Humans; Hydroxyindoleacetic Acid; Naltrexone; Narcotic Antagonists; Personality Disorders; Risk Factors; Selective Serotonin Reuptake Inhibitors; Sleep Initiation and Maintenance Disorders; Suicide; Suicide, Attempted; Taurine

2006
Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.
    Pharmacology & therapeutics, 2006, Volume: 111, Issue:3

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Baclofen; Corticotropin-Releasing Hormone; Disease Models, Animal; Disulfiram; Fructose; Humans; Naltrexone; Neuropeptide Y; Nociceptin; Ondansetron; Opioid Peptides; Receptor, Cannabinoid, CB1; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Taurine; Topiramate

2006
Pharmacotherapy for alcohol dependence: anticraving medications for relapse prevention.
    Yonsei medical journal, 2006, Apr-30, Volume: 47, Issue:2

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; gamma-Aminobutyric Acid; Glutamine; Humans; Models, Biological; Models, Neurological; N-Methylaspartate; Naltrexone; Narcotic Antagonists; Neurons; Polymorphism, Genetic; Receptors, Opioid, mu; Recurrence; Taurine

2006
Choosing the right medication for the treatment of alcoholism.
    Current psychiatry reports, 2006, Volume: 8, Issue:5

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Choice Behavior; Cognitive Behavioral Therapy; Combined Modality Therapy; Fructose; Humans; Naltrexone; Narcotic Antagonists; Neuroprotective Agents; Taurine; Topiramate

2006
[Neurobiological mechanisms and pharmacological treatment options for alcohol craving].
    Fortschritte der Neurologie-Psychiatrie, 2007, Volume: 75, Issue:1

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Disulfiram; Humans; Naltrexone; Narcotic Antagonists; Neurosecretory Systems; Neurotransmitter Agents; Receptors, Glutamate; Taurine

2007
New pharmacological approaches for the treatment of alcoholism.
    Expert opinion on pharmacotherapy, 2006, Volume: 7, Issue:17

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Carbamazepine; Depression; Disease Models, Animal; Disulfiram; Fructose; Humans; Naltrexone; Secondary Prevention; Taurine; Topiramate

2006
Trends in the adoption of medications for alcohol dependence.
    Journal of clinical psychopharmacology, 2006, Volume: 26 Suppl 1

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Humans; Longitudinal Studies; Naltrexone; Narcotic Antagonists; Selective Serotonin Reuptake Inhibitors; Taurine; United States

2006
[Pharmacological relapse prevention in alcohol and tobacco dependence].
    Der Internist, 2007, Volume: 48, Issue:1

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Clinical Trials as Topic; Combined Modality Therapy; Disulfiram; Humans; Naltrexone; Nicotine; Psychotherapy; Secondary Prevention; Smoking Cessation; Substance Withdrawal Syndrome; Taurine; Tobacco Use Disorder

2007
Preclinical and clinical pharmacology of alcohol dependence.
    Fundamental & clinical pharmacology, 2007, Volume: 21, Issue:1

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Disulfiram; Dopamine; GABA Modulators; Glutamic Acid; Humans; Naltrexone; Narcotic Antagonists; Serotonin; Taurine

2007
Emerging approaches to managing alcohol dependence.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2007, Mar-01, Volume: 64, Issue:5 Suppl 3

    Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Behavior Therapy; Brain; Disulfiram; Drug Therapy, Combination; Ethanol; Humans; Naltrexone; Taurine

2007
Improving adherence in patients with alcohol dependence: a new role for pharmacists.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2007, Mar-01, Volume: 64, Issue:5 Suppl 3

    Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Behavior Therapy; Disulfiram; Humans; Naltrexone; Patient Compliance; Pharmacists; Professional Role; Taurine; Treatment Refusal

2007
Substance abuse and schizophrenia: pharmacotherapeutic intervention.
    Journal of substance abuse treatment, 2008, Volume: 34, Issue:1

    Topics: Acamprosate; Alcohol Deterrents; Antipsychotic Agents; Clozapine; Disulfiram; Drug Interactions; Humans; Naltrexone; Narcotics; Schizophrenia; Substance-Related Disorders; Taurine

2008
Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings.
    Biochemical pharmacology, 2008, Jan-01, Volume: 75, Issue:1

    Topics: Acamprosate; Alcoholism; Animals; Baclofen; Disulfiram; Fructose; Humans; Naltrexone; Ondansetron; Receptors, N-Methyl-D-Aspartate; Ritanserin; Selective Serotonin Reuptake Inhibitors; Taurine; Topiramate

2008
Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes.
    Journal of psychopharmacology (Oxford, England), 2008, Volume: 22, Issue:1

    Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Humans; Middle Aged; Naltrexone; Narcotic Antagonists; Publication Bias; Secondary Prevention; Taurine

2008
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Substance Use and Related Disorders, Part 1: Alcoholism.
    The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, 2008, Volume: 9, Issue:1

    Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Biological Psychiatry; Carbamazepine; Disulfiram; Fructose; Health Planning Guidelines; Humans; Naltrexone; Ondansetron; Societies, Scientific; Substance-Related Disorders; Taurine; Topiramate

2008
[Alcohol dependence: diagnosis and treatment].
    La Revue de medecine interne, 2008, Volume: 29, Issue:4

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Cognitive Behavioral Therapy; Disulfiram; Humans; Motivation; Naltrexone; Narcotic Antagonists; Substance Withdrawal Syndrome; Taurine

2008
The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence: a relative benefits analysis of randomized controlled trials.
    The American journal of drug and alcohol abuse, 2008, Volume: 34, Issue:4

    Topics: Acamprosate; Adolescent; Adult; Aged; Alcohol Deterrents; Alcoholism; Female; Follow-Up Studies; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Single-Blind Method; Taurine

2008
The state of pharmacotherapy for the treatment of alcohol dependence.
    Journal of substance abuse treatment, 2009, Volume: 36, Issue:1

    Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Baclofen; Delayed-Action Preparations; Disulfiram; Fructose; Humans; Medication Adherence; Naltrexone; Taurine; Temperance; Topiramate

2009
[Recent results in relaps prevention of alcoholism with Disulfiram].
    Neuropsychiatrie : Klinik, Diagnostik, Therapie und Rehabilitation : Organ der Gesellschaft Osterreichischer Nervenarzte und Psychiater, 2008, Volume: 22, Issue:4

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Aldehyde Dehydrogenase; Combined Modality Therapy; Disulfiram; Drug Interactions; Drug Therapy, Combination; Germany; Humans; Metabolic Clearance Rate; Motivation; Naltrexone; Randomized Controlled Trials as Topic; Secondary Prevention; Taurine

2008
Opioid antagonists for pharmacological treatment of alcohol dependence - a critical review.
    Current drug abuse reviews, 2008, Volume: 1, Issue:3

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Cognitive Behavioral Therapy; Combined Modality Therapy; Delayed-Action Preparations; Dopamine; Drug Therapy, Combination; Humans; Motivation; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Receptors, Opioid; Secondary Prevention; Taurine; Temperance; Ventral Tegmental Area

2008
Addiction treatment: level of care determination.
    Primary care, 2011, Volume: 38, Issue:1

    Topics: Acamprosate; Alcohol Deterrents; Behavior Therapy; Cognitive Behavioral Therapy; Health Status Indicators; Humans; Inpatients; Mass Screening; Naltrexone; Narcotic Antagonists; Outpatients; Primary Health Care; Substance-Related Disorders; Taurine

2011
How cognitive assessment through clinical neurophysiology may help optimize chronic alcoholism treatment.
    Neurophysiologie clinique = Clinical neurophysiology, 2011, Volume: 41, Issue:3

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Cognition; Humans; Naltrexone; Psychotherapy; Taurine

2011
Strategies for evaluating the economic value of drugs in alcohol dependence treatment.
    Drug and alcohol dependence, 2012, May-01, Volume: 122, Issue:3

    Topics: Acamprosate; Alcoholism; Clinical Trials as Topic; Cost-Benefit Analysis; Humans; Naltrexone; Taurine; Treatment Outcome

2012
Opioid antagonists for the treatment of alcohol dependence.
    American family physician, 2011, Nov-01, Volume: 84, Issue:9

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Motivation; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Secondary Prevention; Taurine; Treatment Outcome

2011
[Meta-analysis of pharmacological therapy with acamprosate, naltrexone, and disulfiram--a systematic review].
    Ugeskrift for laeger, 2011, Nov-28, Volume: 173, Issue:48

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Evidence-Based Medicine; Humans; Naltrexone; Taurine; Treatment Outcome

2011
New pharmacological treatment strategies for relapse prevention.
    Current topics in behavioral neurosciences, 2013, Volume: 13

    Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Animals; Disulfiram; Drugs, Investigational; History, 18th Century; History, 21st Century; Humans; Naltrexone; Receptors, N-Methyl-D-Aspartate; Secondary Prevention; Taurine

2013
Medical treatment of alcohol dependence: a systematic review.
    International journal of psychiatry in medicine, 2011, Volume: 42, Issue:3

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Fructose; Humans; Naltrexone; Narcotic Antagonists; Off-Label Use; Taurine; Topiramate; Treatment Outcome

2011
[Relapse prevention in alcohol dependence: acamprosate and naltrexone as a combined pharmacological strategy].
    Der Nervenarzt, 2013, Volume: 84, Issue:5

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Drug Therapy, Combination; Female; Humans; Middle Aged; Naltrexone; Secondary Prevention; Taurine; Treatment Outcome

2013
Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful?
    Addiction (Abingdon, England), 2013, Volume: 108, Issue:2

    Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Ethanol; Humans; Inactivation, Metabolic; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Taurine; Time Factors; Treatment Outcome

2013
The current situation of treatment systems for alcoholism in Korea.
    Journal of Korean medical science, 2013, Volume: 28, Issue:2

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Benzodiazepines; Humans; Naltrexone; Psychotherapy; Republic of Korea; Taurine

2013
Medications for unhealthy alcohol use: across the spectrum.
    Alcohol research & health : the journal of the National Institute on Alcohol Abuse and Alcoholism, 2011, Volume: 33, Issue:4

    Topics: Acamprosate; Alcohol Drinking; Alcoholism; Animals; Disulfiram; Dopamine Agents; Fructose; Humans; Naltrexone; Selective Serotonin Reuptake Inhibitors; Taurine; Topiramate

2011
Treatment implications: using neuroscience to guide the development of new pharmacotherapies for alcoholism.
    Alcohol research & health : the journal of the National Institute on Alcohol Abuse and Alcoholism, 2008, Volume: 31, Issue:4

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Brain Chemistry; Disulfiram; Humans; Naltrexone; Narcotic Antagonists; Taurine; Treatment Outcome

2008
Pharmacotherapy for alcohol dependence: status of current treatments.
    Current opinion in neurobiology, 2013, Volume: 23, Issue:4

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Clinical Trials as Topic; Disulfiram; Humans; Multicenter Studies as Topic; Naltrexone; Narcotic Antagonists; Taurine

2013
Research opportunities for medications to treat alcohol dependence: addressing stakeholders' needs.
    Alcoholism, clinical and experimental research, 2014, Volume: 38, Issue:1

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Biomedical Research; Drug Industry; Health Services Needs and Demand; Humans; Insurance, Health, Reimbursement; Naltrexone; Narcotic Antagonists; Taurine

2014
The placebo effect in clinical trials for alcohol dependence: an exploratory analysis of 51 naltrexone and acamprosate studies.
    Alcoholism, clinical and experimental research, 2013, Volume: 37, Issue:12

    Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Placebo Effect; Randomized Controlled Trials as Topic; Taurine; Treatment Outcome

2013
[New treatment options for alcohol dependence].
    MMW Fortschritte der Medizin, 2013, May-02, Volume: 155, Issue:8

    Topics: Acamprosate; Alcoholism; Baclofen; Combined Modality Therapy; Ethanol; Fructose; Humans; Naltrexone; Psychotherapy; Secondary Prevention; Socioenvironmental Therapy; Substance Withdrawal Syndrome; Taurine; Topiramate

2013
Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis.
    JAMA, 2014, May-14, Volume: 311, Issue:18

    Topics: Acamprosate; Alcohol-Related Disorders; Fructose; Harm Reduction; Humans; Naltrexone; Outpatients; Randomized Controlled Trials as Topic; Taurine; Topiramate

2014
A Bayesian mixed-treatment comparison meta-analysis of treatments for alcohol dependence and implications for planning future trials.
    Medical decision making : an international journal of the Society for Medical Decision Making, 2014, Volume: 34, Issue:7

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Bayes Theorem; Humans; Naltrexone; Randomized Controlled Trials as Topic; Review Literature as Topic; Taurine

2014
Alcohol use disorders and current pharmacological therapies: the role of GABA(A) receptors.
    Acta pharmacologica Sinica, 2014, Volume: 35, Issue:8

    Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Animals; Benzodiazepines; Disulfiram; Ethanol; Fructose; Humans; Naltrexone; Narcotic Antagonists; Neuroprotective Agents; Plant Preparations; Receptors, GABA-A; Taurine; Topiramate

2014
Medications for addiction treatment: an opportunity for prescribing clinicians to facilitate remission from alcohol and opioid use disorders.
    Rhode Island medical journal (2013), 2014, Oct-01, Volume: 97, Issue:10

    Topics: Acamprosate; Analgesics, Opioid; Behavior, Addictive; Buprenorphine; Directive Counseling; Disulfiram; Humans; Methadone; Naltrexone; Narcotic Antagonists; Practice Patterns, Physicians'; Substance-Related Disorders; Taurine; United States

2014
Pharmacologic treatment of alcoholism.
    Handbook of clinical neurology, 2014, Volume: 125

    Topics: Acamprosate; Alcoholism; Animals; Brain; Humans; Naltrexone; Nerve Net; Neuroimaging; Pharmacogenetics; Taurine; Valproic Acid

2014
Treatment of alcohol dependence: recent progress and reduction of consumption.
    Minerva medica, 2014, Volume: 105, Issue:6

    Topics: Acamprosate; Age of Onset; Alcohol Deterrents; Alcohol-Related Disorders; Alcoholism; Binge Drinking; Contraindications; Craving; Disulfiram; Drugs, Investigational; Europe; Humans; Meta-Analysis as Topic; Multicenter Studies as Topic; Naltrexone; Neurotransmitter Agents; Randomized Controlled Trials as Topic; Sodium Oxybate; Taurine

2014
The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence, Europe versus the rest of the world: a meta-analysis.
    Addiction (Abingdon, England), 2015, Volume: 110, Issue:6

    Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Europe; Female; Global Health; Humans; Male; Middle Aged; Naltrexone; Randomized Controlled Trials as Topic; Recurrence; Taurine; Treatment Outcome

2015
Recent Developments in Pharmacotherapy of Alcoholism.
    Pharmacopsychiatry, 2015, Volume: 48, Issue:4-5

    Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Anticonvulsants; Baclofen; Humans; Naltrexone; Narcotic Antagonists; Pharmacogenetics; Randomized Controlled Trials as Topic; Taurine; Varenicline

2015
Efficacy of Medications Approved for the Treatment of Alcohol Dependence and Alcohol Withdrawal Syndrome in Female Patients: A Descriptive Review.
    European addiction research, 2016, Volume: 22, Issue:1

    Topics: Acamprosate; Alcohol Deterrents; Alcohol Withdrawal Delirium; Alcoholism; Anticonvulsants; Benzodiazepines; Disulfiram; Female; Humans; Male; Naltrexone; Sex Factors; Taurine; Treatment Outcome

2016
[Depression in alcohol addicted patients].
    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2015, Volume: 115, Issue:7

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Antidepressive Agents; Comorbidity; Depressive Disorder; Disulfiram; Humans; Naltrexone; Narcotic Antagonists; Psychotherapy; Selective Serotonin Reuptake Inhibitors; Substance Withdrawal Syndrome; Taurine

2015
[Pharmacological therapies for alcohol use disorder in Japan].
    Nihon rinsho. Japanese journal of clinical medicine, 2015, Volume: 73, Issue:9

    Topics: Acamprosate; Alcohol-Related Disorders; Alcohols; Humans; Japan; Naltrexone; Substance Withdrawal Syndrome; Taurine

2015
Pharmacogenetics of alcohol use disorders and comorbid psychiatric disorders.
    Psychiatry research, 2015, Dec-15, Volume: 230, Issue:2

    Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Anxiety Disorders; Comorbidity; Depressive Disorder, Major; Disulfiram; Fructose; Humans; Naltrexone; Pharmacogenetics; Precision Medicine; Taurine; Topiramate; United States

2015
NEUROBIOLOGICAL BASES OF ALCOHOL ADDICTION.
    Acta clinica Croatica, 2016, Volume: 55, Issue:1

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Brain; Disulfiram; Dopamine; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Minisatellite Repeats; Monoamine Oxidase; Naltrexone; Narcotic Antagonists; Neuropeptide Y; Norepinephrine; Ondansetron; Polymorphism, Genetic; Serotonin; Synaptic Transmission; Taurine

2016
Supervised Disulfiram's Superior Effectiveness in Alcoholism Treatment: Ethical, Methodological, and Psychological Aspects.
    Alcohol and alcoholism (Oxford, Oxfordshire), 2017, Mar-09, Volume: 52, Issue:2

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Bioethical Issues; Disulfiram; Humans; Naltrexone; Taurine

2017
Review article: pharmacotherapy for alcohol dependence - the why, the what and the wherefore.
    Alimentary pharmacology & therapeutics, 2017, Volume: 45, Issue:7

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Baclofen; Disulfiram; Drug Combinations; Fructose; Humans; Naltrexone; Polymorphism, Single Nucleotide; Pyridoxine; Pyrrolidonecarboxylic Acid; Taurine; Topiramate; Treatment Outcome

2017
Personalized Medicine of Alcohol Addiction: Pharmacogenomics and Beyond.
    Current pharmaceutical biotechnology, 2017, Volume: 18, Issue:3

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Humans; Naltrexone; Pharmacogenetics; Polymorphism, Genetic; Precision Medicine; Taurine

2017
The Glycine Receptor-A Functionally Important Primary Brain Target of Ethanol.
    Alcoholism, clinical and experimental research, 2017, Volume: 41, Issue:11

    Topics: Acamprosate; Alcohol Drinking; Animals; Brain; Dopamine; Ethanol; Humans; Naltrexone; Receptors, Glycine; Taurine

2017
Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate.
    Addiction (Abingdon, England), 2018, Volume: 113, Issue:2

    Topics: Acamprosate; Alcoholism; Baclofen; Naltrexone; Narcotic Antagonists; Network Meta-Analysis; Topiramate; Treatment Outcome

2018
Advances in Pharmacotherapy Development: Human Clinical Studies.
    Handbook of experimental pharmacology, 2018, Volume: 248

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Humans; Naltrexone

2018
Study characteristics influence the efficacy of substance abuse treatments: A meta-analysis of medications for alcohol use disorder.
    Drug and alcohol dependence, 2018, Sep-01, Volume: 190

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Female; Humans; Male; Middle Aged; Naltrexone; Randomized Controlled Trials as Topic; Substance-Related Disorders; Taurine; Treatment Outcome

2018
Diagnosis and Pharmacotherapy of Alcohol Use Disorder: A Review.
    JAMA, 2018, 08-28, Volume: 320, Issue:8

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Counseling; Disulfiram; Humans; Naltrexone; Taurine

2018
Strategies to increase implementation of pharmacotherapy for alcohol use disorders: a structured review of care delivery and implementation interventions.
    Addiction science & clinical practice, 2019, 02-12, Volume: 14, Issue:1

    Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Alcoholism; Clinical Trials as Topic; Disulfiram; Naltrexone; Practice Patterns, Physicians'; Topiramate; United States; United States Department of Veterans Affairs; Veterans

2019
Selecting an appropriate alcohol pharmacotherapy: review of recent findings.
    Current opinion in psychiatry, 2019, Volume: 32, Issue:4

    Topics: Acamprosate; Alcoholism; Antidepressive Agents; Baclofen; Cholinergic Agonists; Disulfiram; Gabapentin; Humans; Naltrexone; Ondansetron; Randomized Controlled Trials as Topic; Treatment Outcome

2019
Medication Development for Alcohol Use Disorder: A Focus on Clinical Studies.
    Handbook of experimental pharmacology, 2020, Volume: 258

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Drug Development; Humans; Naltrexone

2020
Evidence-Based Pharmacotherapies for Alcohol Use Disorder: Clinical Pearls.
    Mayo Clinic proceedings, 2020, Volume: 95, Issue:9

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Anticonvulsants; Disulfiram; Evidence-Based Medicine; Humans; Mass Screening; Naltrexone; Off-Label Use; Practice Guidelines as Topic

2020
[Pharmacotherapy of alcohol withdrawal: update and new developments].
    Der Nervenarzt, 2021, Volume: 92, Issue:1

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Germany; Humans; Naltrexone; Narcotic Antagonists; Taurine

2021
Pharmacotherapies for the Treatment of Alcohol Use Disorders During Pregnancy: Time to Reconsider?
    Drugs, 2021, Volume: 81, Issue:7

    Topics: Acamprosate; Alcohol Abstinence; Alcohol Deterrents; Alcoholism; Animals; Comorbidity; Disulfiram; Female; Fetal Alcohol Spectrum Disorders; Humans; Naltrexone; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Substance Withdrawal Syndrome

2021
Alcohol Use Disorder: The Role of Medication in Recovery.
    Alcohol research : current reviews, 2021, Volume: 41, Issue:1

    Topics: Acamprosate; Alcoholism; Humans; Naltrexone; Pharmaceutical Preparations; Quality of Life; United States

2021
Review of Evidence-Based Strategies to Treat Alcohol Use Disorder.
    Journal of psychosocial nursing and mental health services, 2021, Volume: 59, Issue:12

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Humans; Naltrexone

2021
Treatment of alcohol use disorder in patients with liver disease.
    Current opinion in pharmacology, 2022, Volume: 62

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Humans; Liver Diseases; Naltrexone; Narcotic Antagonists; Treatment Outcome

2022
Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder.
    Drugs, 2022, Volume: 82, Issue:3

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Baclofen; Disulfiram; Humans; Naltrexone; Topiramate

2022
Perspectives on the pharmacological management of alcohol use disorder: Are the approved medications effective?
    European journal of internal medicine, 2022, Volume: 103

    Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Disulfiram; Humans; Naltrexone

2022
Integration of pharmacotherapy for alcohol use disorder treatment in primary care settings: A scoping review.
    Journal of substance abuse treatment, 2023, Volume: 144

    Topics: Acamprosate; Adolescent; Alcohol Drinking; Alcoholism; Disulfiram; Humans; Naltrexone; Primary Health Care; Randomized Controlled Trials as Topic; United States

2023
Baclofen for alcohol use disorder.
    The Cochrane database of systematic reviews, 2023, 01-13, Volume: 1

    Topics: Acamprosate; Adult; Alcohol Drinking; Alcoholism; Baclofen; Chronic Disease; Female; Humans; Male; Middle Aged; Naltrexone

2023
Psychosocial and pharmacologic interventions to reduce harmful alcohol use in low- and middle-income countries.
    The Cochrane database of systematic reviews, 2023, 05-09, Volume: 5

    Topics: Acamprosate; Alcoholism; Amitriptyline; Developing Countries; Disulfiram; Humans; Male; Mirtazapine; Naltrexone; Ondansetron; Topiramate

2023
Overview of Alcohol Use Disorder.
    The American journal of psychiatry, 2023, 08-01, Volume: 180, Issue:8

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Child; Disulfiram; Ethanol; Humans; Naltrexone; United States

2023
Medication treatment for alcohol use disorder in special populations.
    The American journal on addictions, 2023, Volume: 32, Issue:5

    Topics: Acamprosate; Adolescent; Alcoholism; Analgesics, Opioid; Disulfiram; Humans; Naltrexone; Narcotic Antagonists

2023
Pharmacotherapy for Alcohol Use Disorder: A Systematic Review and Meta-Analysis.
    JAMA, 2023, 11-07, Volume: 330, Issue:17

    Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Drug-Related Side Effects and Adverse Reactions; Humans; Naltrexone; Prospective Studies; Psychosocial Intervention; Quality of Life; United States

2023

Trials

48 trial(s) available for naltrexone and acamprosate

ArticleYear
Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis.
    Alcoholism, clinical and experimental research, 2001, Volume: 25, Issue:9

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Depression; Female; gamma-Glutamyltransferase; Humans; Male; Naltrexone; Narcotic Antagonists; Placebos; Secondary Prevention; Selective Serotonin Reuptake Inhibitors; Taurine; Treatment Outcome

2001
A pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2002, Volume: 27, Issue:4

    Topics: Acamprosate; Adolescent; Adult; Alcohol Deterrents; Alcoholism; Brain; Cognition; Double-Blind Method; Drug Interactions; Drug Tolerance; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Neuropsychological Tests; Reaction Time; Taurine

2002
Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study.
    Archives of general psychiatry, 2003, Volume: 60, Issue:1

    Topics: Acamprosate; Alcoholism; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Naltrexone; Placebos; Secondary Prevention; Taurine; Treatment Outcome

2003
Dose-ranging kinetics and behavioral pharmacology of naltrexone and acamprosate, both alone and combined, in alcohol-dependent subjects.
    Journal of clinical psychopharmacology, 2003, Volume: 23, Issue:3

    Topics: Acamprosate; Adult; Alcoholism; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Naltrexone; Neuropsychological Tests; Taurine

2003
Testing combined pharmacotherapies and behavioral interventions in alcohol dependence: rationale and methods.
    Alcoholism, clinical and experimental research, 2003, Volume: 27, Issue:7

    Topics: Acamprosate; Alcoholism; Analysis of Variance; Behavior Therapy; Drug Therapy, Combination; Female; Humans; Male; Naltrexone; Randomized Controlled Trials as Topic; Taurine

2003
Testing combined pharmacotherapies and behavioral interventions for alcohol dependence (the COMBINE study): a pilot feasibility study.
    Alcoholism, clinical and experimental research, 2003, Volume: 27, Issue:7

    Topics: Acamprosate; Adult; Alcoholism; Behavior Therapy; Double-Blind Method; Drug Therapy, Combination; Feasibility Studies; Female; Humans; Male; Middle Aged; Naltrexone; Pilot Projects; Taurine

2003
Pharmacological relapse prevention of alcoholism: clinical predictors of outcome.
    European addiction research, 2005, Volume: 11, Issue:2

    Topics: Acamprosate; Adolescent; Adult; Aged; Alcohol Deterrents; Alcoholism; Anxiety Disorders; Depression; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Female; Humans; Male; Middle Aged; Naltrexone; Narcotics; Predictive Value of Tests; Prospective Studies; Secondary Prevention; Somatoform Disorders; Surveys and Questionnaires; Taurine; Treatment Outcome

2005
Increasing leptin precedes craving and relapse during pharmacological abstinence maintenance treatment of alcoholism.
    Journal of psychiatric research, 2005, Volume: 39, Issue:5

    Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Double-Blind Method; Female; Humans; Leptin; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Placebos; Recurrence; Taurine

2005
Hypothalamic-pituitary-adrenocortical axis activity: a target of pharmacological anticraving treatment?
    Biological psychiatry, 2006, Jul-01, Volume: 60, Issue:1

    Topics: Acamprosate; Adrenocorticotropic Hormone; Adult; Alcohol Deterrents; Alcoholism; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydrocortisone; Hypothalamo-Hypophyseal System; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Pituitary-Adrenal System; Taurine; Time Factors

2006
Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.
    JAMA, 2006, May-03, Volume: 295, Issue:17

    Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Behavior Therapy; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Placebo Effect; Taurine

2006
Naltrexone versus acamprosate in the treatment of alcohol dependence: A multi-centre, randomized, double-blind, placebo-controlled trial.
    Addiction (Abingdon, England), 2006, Volume: 101, Issue:10

    Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol-Related Disorders; Anxiety; Australia; Depressive Disorder; Double-Blind Method; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Patient Compliance; Placebos; Secondary Prevention; Taurine; Treatment Outcome

2006
Psychometrics of the Drinker Inventory of Consequences (DrInC).
    Addictive behaviors, 2007, Volume: 32, Issue:8

    Topics: Acamprosate; Alcoholism; Combined Modality Therapy; Factor Analysis, Statistical; Follow-Up Studies; Humans; Naltrexone; Narcotic Antagonists; Psychometrics; Psychotherapy; Surveys and Questionnaires; Taurine

2007
Measuring economic outcomes of alcohol treatment using the Economic Form 90.
    Journal of studies on alcohol and drugs, 2007, Volume: 68, Issue:2

    Topics: Absenteeism; Acamprosate; Accidents, Traffic; Adult; Alcohol Deterrents; Alcoholism; Behavior Therapy; Combined Modality Therapy; Cost-Benefit Analysis; Criminal Law; Employment; Female; Follow-Up Studies; Health Care Costs; Health Resources; Humans; Male; Middle Aged; Models, Economic; Naltrexone; Prisons; Taurine; Treatment Outcome; United States

2007
The effect of naltrexone and acamprosate on cue-induced craving, autonomic nervous system and neuroendocrine reactions to alcohol-related cues in alcoholics.
    European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2007, Volume: 17, Issue:8

    Topics: Acamprosate; Affect; Alcohol Deterrents; Alcoholism; Autonomic Nervous System; Cues; Double-Blind Method; Galvanic Skin Response; Heart Rate; Humans; Hydrocortisone; Naltrexone; Narcotic Antagonists; Neurosecretory Systems; Patient Compliance; Psychiatric Status Rating Scales; Surveys and Questionnaires; Taurine

2007
An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study.
    Archives of general psychiatry, 2008, Volume: 65, Issue:2

    Topics: Acamprosate; Adult; Alcoholism; Alleles; Amino Acid Substitution; Asparagine; Aspartic Acid; Cognitive Behavioral Therapy; Combined Modality Therapy; Drug Therapy, Combination; Female; Genetic Carrier Screening; Genetic Markers; Genotype; Homozygote; Humans; Liver Function Tests; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Pharmacogenetics; Polymorphism, Genetic; Prognosis; Receptors, Opioid, mu; Taurine; Temperance; Treatment Outcome

2008
Do acamprosate or naltrexone have an effect on daily drinking by reducing craving for alcohol?
    Addiction (Abingdon, England), 2008, Volume: 103, Issue:6

    Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Behavior, Addictive; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Patient Compliance; Taurine; Treatment Outcome

2008
Relationship between medication adherence and treatment outcomes: the COMBINE study.
    Alcoholism, clinical and experimental research, 2008, Volume: 32, Issue:9

    Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Behavior Therapy; Combined Modality Therapy; Female; Humans; Male; Medication Adherence; Middle Aged; Naltrexone; National Institute on Alcohol Abuse and Alcoholism (U.S.); Taurine; Temperance; Treatment Outcome; United States

2008
Cost and cost-effectiveness of the COMBINE study in alcohol-dependent patients.
    Archives of general psychiatry, 2008, Volume: 65, Issue:10

    Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Behavior Therapy; Combined Modality Therapy; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Naltrexone; Taurine; Temperance

2008
Do patients with alcohol dependence respond to placebo? Results from the COMBINE Study.
    Journal of studies on alcohol and drugs, 2008, Volume: 69, Issue:6

    Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholics Anonymous; Alcoholism; Cognitive Behavioral Therapy; Combined Modality Therapy; Double-Blind Method; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Negativism; Placebo Effect; Secondary Prevention; Taurine; Temperance; Treatment Outcome

2008
Searching for responders to acamprosate and naltrexone in alcoholism treatment: rationale and design of the PREDICT study.
    Alcoholism, clinical and experimental research, 2009, Volume: 33, Issue:4

    Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Combined Modality Therapy; Dopamine Agents; Double-Blind Method; Excitatory Amino Acid Agents; Female; Germany; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Naltrexone; Positron-Emission Tomography; Predictive Value of Tests; Prognosis; Psychotherapy; Reflex; Taurine; United States; Young Adult

2009
Blood glucose level, alcohol heavy drinking, and alcohol craving during treatment for alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) Study.
    Alcoholism, clinical and experimental research, 2009, Volume: 33, Issue:9

    Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Behavior Therapy; Blood Glucose; Counseling; Female; Humans; Male; Middle Aged; Naltrexone; Obsessive-Compulsive Disorder; Psychiatric Status Rating Scales; Taurine

2009
Predicting the effect of naltrexone and acamprosate in alcohol-dependent patients using genetic indicators.
    Addiction biology, 2009, Volume: 14, Issue:3

    Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Cues; Female; Genotype; Humans; Male; Middle Aged; Motivation; Naltrexone; Narcotic Antagonists; Pharmacogenetics; Polymorphism, Genetic; Receptors, Dopamine D2; Receptors, GABA-A; Receptors, Opioid, mu; Taurine; Treatment Outcome

2009
Naltrexone for the treatment of alcohol dependence among African Americans: results from the COMBINE Study.
    Drug and alcohol dependence, 2009, Dec-01, Volume: 105, Issue:3

    Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Behavior Therapy; Black or African American; Combined Modality Therapy; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Taurine; Treatment Outcome

2009
[Impact of functional social support for abstinence after inpatient detoxification].
    Neuropsychiatrie : Klinik, Diagnostik, Therapie und Rehabilitation : Organ der Gesellschaft Osterreichischer Nervenarzte und Psychiater, 2010, Volume: 24, Issue:2

    Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Combined Modality Therapy; Double-Blind Method; Drug Therapy, Combination; Female; Hospitalization; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Outcome Assessment, Health Care; Prognosis; Prospective Studies; Psychotherapy, Group; Retreatment; Secondary Prevention; Social Support; Surveys and Questionnaires; Taurine

2010
Network support as a prognostic indicator of drinking outcomes: the COMBINE Study.
    Journal of studies on alcohol and drugs, 2010, Volume: 71, Issue:6

    Topics: Acamprosate; Adult; Alcohol Drinking; Alcoholism; Female; Humans; Male; Naltrexone; Prognosis; Social Support; Taurine; Temperance; Treatment Outcome

2010
Does family history of alcoholism moderate naltrexone's effects on alcohol use?
    Journal of studies on alcohol and drugs, 2011, Volume: 72, Issue:1

    Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Behavior Therapy; Family; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Patient Compliance; Placebos; Sex Characteristics; Substance-Related Disorders; Taurine; Treatment Outcome

2011
Baseline trajectories of drinking moderate acamprosate and naltrexone effects in the COMBINE study.
    Alcoholism, clinical and experimental research, 2011, Volume: 35, Issue:3

    Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Taurine; Temperance

2011
Moderating effects of a craving intervention on the relation between negative mood and heavy drinking following treatment for alcohol dependence.
    Journal of consulting and clinical psychology, 2011, Volume: 79, Issue:1

    Topics: Acamprosate; Adult; Affect; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Behavior Therapy; Combined Modality Therapy; Factor Analysis, Statistical; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Taurine; Treatment Outcome

2011
Self-efficacy change as a mediator of associations between therapeutic bond and one-year outcomes in treatments for alcohol dependence.
    Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors, 2011, Volume: 25, Issue:2

    Topics: Acamprosate; Adolescent; Adult; Aged; Aged, 80 and over; Alcohol Deterrents; Alcoholism; Behavior Therapy; Combined Modality Therapy; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Professional-Patient Relations; Self Efficacy; Taurine; Treatment Outcome

2011
Baseline trajectories of heavy drinking and their effects on postrandomization drinking in the COMBINE Study: empirically derived predictors of drinking outcomes during treatment.
    Alcohol (Fayetteville, N.Y.), 2012, Volume: 46, Issue:2

    Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Behavior Therapy; Combined Modality Therapy; Female; Humans; Male; Middle Aged; Naltrexone; Random Allocation; Taurine; Temperance; Treatment Outcome

2012
Does session attendance by a supportive significant other predict outcomes in individual treatment for alcohol use disorders?
    Alcoholism, clinical and experimental research, 2012, Volume: 36, Issue:7

    Topics: Acamprosate; Adult; Alcohol-Related Disorders; Alcoholism; Behavior Therapy; Combined Modality Therapy; Female; Forecasting; Humans; Male; Middle Aged; Naltrexone; Social Support; Spouses; Taurine; Treatment Outcome

2012
The cost-effectiveness of tailored, postal feedback on general practitioners' prescribing of pharmacotherapies for alcohol dependence.
    Drug and alcohol dependence, 2012, Aug-01, Volume: 124, Issue:3

    Topics: Acamprosate; Adolescent; Adult; Alcoholism; Cost-Benefit Analysis; Female; General Practitioners; Humans; Male; Naltrexone; New South Wales; Postal Service; Practice Patterns, Physicians'; Taurine

2012
Trajectory analyses in alcohol treatment research.
    Alcoholism, clinical and experimental research, 2012, Volume: 36, Issue:8

    Topics: Acamprosate; Adult; Aged; Aged, 80 and over; Alcohol Deterrents; Alcoholism; Algorithms; Behavior Therapy; Combined Modality Therapy; Data Interpretation, Statistical; Double-Blind Method; Female; Fructose; Humans; Linear Models; Male; Middle Aged; Models, Statistical; Naltrexone; Narcotic Antagonists; Neuroprotective Agents; Nonlinear Dynamics; Regression Analysis; Research; Research Design; Taurine; Topiramate; Treatment Outcome; Young Adult

2012
Cigarette smoking predicts differential benefit from naltrexone for alcohol dependence.
    Biological psychiatry, 2012, Nov-15, Volume: 72, Issue:10

    Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Behavior Therapy; Combined Modality Therapy; Comorbidity; Drug Interactions; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Smoking; Taurine; Treatment Outcome

2012
Simultaneous modeling of the impact of treatments on alcohol consumption and quality of life in the COMBINE study: a coupled hidden Markov analysis.
    Alcoholism, clinical and experimental research, 2012, Volume: 36, Issue:12

    Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Behavior Therapy; Combined Modality Therapy; Drug Therapy, Combination; Humans; Markov Chains; Naltrexone; Quality of Life; Taurine; Treatment Outcome

2012
Results of a double-blind, placebo-controlled pharmacotherapy trial in alcoholism conducted in Germany and comparison with the US COMBINE study.
    Addiction biology, 2013, Volume: 18, Issue:6

    Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Ambulatory Care; Counseling; Disease-Free Survival; Double-Blind Method; Female; Germany; Hospitalization; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Medication Adherence; Middle Aged; Naltrexone; Narcotic Antagonists; Patient Education as Topic; Placebos; Randomized Controlled Trials as Topic; Research Design; Taurine; Treatment Outcome; United States

2013
The effects of drinking goal on treatment outcome for alcoholism.
    Journal of consulting and clinical psychology, 2013, Volume: 81, Issue:1

    Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Cognitive Behavioral Therapy; Female; Goals; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Recurrence; Taurine; Treatment Outcome

2013
Modeling longitudinal drinking data in clinical trials: an application to the COMBINE study.
    Drug and alcohol dependence, 2013, Sep-01, Volume: 132, Issue:1-2

    Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Cognitive Behavioral Therapy; Combined Modality Therapy; Data Interpretation, Statistical; Disease Progression; Female; Humans; Longitudinal Studies; Male; Models, Statistical; Naltrexone; Narcotic Antagonists; Poisson Distribution; Risk-Taking; Taurine; Temperance; Treatment Outcome

2013
What happens when people discontinue taking medications? Lessons from COMBINE.
    Addiction (Abingdon, England), 2014, Volume: 109, Issue:12

    Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Behavior Therapy; Combined Modality Therapy; Cross-Sectional Studies; Drug Therapy, Combination; Female; Humans; Longitudinal Studies; Male; Medication Adherence; Middle Aged; Naltrexone; Patient Dropouts; Recurrence; Taurine

2014
Pain as a predictor of heavy drinking and any drinking lapses in the COMBINE study and the UK Alcohol Treatment Trial.
    Addiction (Abingdon, England), 2015, Volume: 110, Issue:8

    Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcohol-Related Disorders; Behavior Therapy; Chronic Pain; Combined Modality Therapy; Female; Humans; Male; Naltrexone; Pain Measurement; Recurrence; Taurine; Treatment Outcome

2015
Therapist empathy, combined behavioral intervention, and alcohol outcomes in the COMBINE research project.
    Journal of consulting and clinical psychology, 2016, Volume: 84, Issue:3

    Topics: Acamprosate; Adaptation, Psychological; Affect; Alcohol Deterrents; Alcoholism; Behavior Therapy; Combined Modality Therapy; Counseling; Empathy; Health Personnel; Humans; Middle Aged; Naltrexone; Taurine; Treatment Outcome

2016
Reward and relief dimensions of temptation to drink: construct validity and role in predicting differential benefit from acamprosate and naltrexone.
    Addiction biology, 2017, Volume: 22, Issue:6

    Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Reproducibility of Results; Reward; Taurine; Treatment Outcome

2017
Effectiveness of Psychoanalytic-Interactional Group Therapy vs. Behavioral Group Therapy in Routine Outpatient Treatment of Alcohol-Dependent Patients.
    Substance use & misuse, 2018, 02-23, Volume: 53, Issue:3

    Topics: Acamprosate; Alcoholism; Cognitive Behavioral Therapy; Combined Modality Therapy; Disulfiram; Female; Humans; Male; Middle Aged; Naltrexone; Outpatients; Psychoanalytic Therapy; Psychotherapy, Group; Recurrence; Secondary Prevention; Taurine; Treatment Outcome

2018
Precision Medicine in Alcohol Dependence: A Controlled Trial Testing Pharmacotherapy Response Among Reward and Relief Drinking Phenotypes.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2018, Volume: 43, Issue:4

    Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Phenotype; Precision Medicine; Reward; Treatment Outcome

2018
Therapeutic Drug Monitoring of Naltrexone and 6β-Naltrexol During Anti-craving Treatment in Alcohol Dependence: Reference Ranges.
    Alcohol and alcoholism (Oxford, Oxfordshire), 2019, Jan-01, Volume: 54, Issue:1

    Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Craving; Double-Blind Method; Drug Monitoring; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Reference Values; Treatment Outcome

2019
World Health Organization risk drinking level reductions are associated with improved functioning and are sustained among patients with mild, moderate and severe alcohol dependence in clinical trials in the United States and United Kingdom.
    Addiction (Abingdon, England), 2020, Volume: 115, Issue:9

    Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcohol-Related Disorders; Alcoholism; Behavior Therapy; Female; Health Surveys; Humans; Male; Mental Health; Middle Aged; Motivational Interviewing; Naltrexone; Risk; Treatment Outcome; United Kingdom; United States; World Health Organization

2020
Differences in Sociodemographic and Alcohol-Related Clinical Characteristics Between Treatment Seekers and Nontreatment Seekers and Their Role in Predicting Outcomes in the COMBINE Study for Alcohol Use Disorder.
    Alcoholism, clinical and experimental research, 2020, Volume: 44, Issue:10

    Topics: Acamprosate; Adult; Age of Onset; Alcohol Deterrents; Alcoholism; Case-Control Studies; Drug Therapy, Combination; Female; Humans; Male; Naltrexone; Patient Acceptance of Health Care; Socioeconomic Factors; Treatment Outcome

2020
Low rates of prescribing alcohol relapse prevention medicines in Australian Aboriginal Community Controlled Health Services.
    Drug and alcohol review, 2023, Volume: 42, Issue:7

    Topics: Acamprosate; Adult; Alcoholism; Australia; Australian Aboriginal and Torres Strait Islander Peoples; Chronic Disease; Disulfiram; Health Services, Indigenous; Humans; Male; Middle Aged; Naltrexone; Secondary Prevention

2023

Other Studies

113 other study(ies) available for naltrexone and acamprosate

ArticleYear
International update: new findings on promising medications.
    Alcoholism, clinical and experimental research, 1996, Volume: 20, Issue:8 Suppl

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Clinical Trials as Topic; Cocaine; Comorbidity; Europe; Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Taurine; United States

1996
Alternatives to naltrexone in animal models.
    Alcoholism, clinical and experimental research, 1996, Volume: 20, Issue:8 Suppl

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Disease Models, Animal; Drug Evaluation, Preclinical; Haplorhini; Humans; Naltrexone; Narcotic Antagonists; Rats; Serotonin Antagonists; Serotonin Receptor Agonists; Taurine; Thyrotropin-Releasing Hormone

1996
New drug treatments for alcohol problems: a critical appraisal.
    Addiction (Abingdon, England), 1997, Volume: 92, Issue:8

    Topics: Acamprosate; Alcoholism; Anti-Anxiety Agents; Buspirone; Dopamine Antagonists; Humans; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Taurine

1997
[Medical treatment of alcohol dependence].
    Revue medicale de la Suisse romande, 1998, Volume: 118, Issue:9

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Humans; Naltrexone; Narcotic Antagonists; Taurine

1998
New treatments for alcohol dependency better than old.
    Lancet (London, England), 1999, Jan-16, Volume: 353, Issue:9148

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Humans; Naltrexone; Taurine

1999
Prevention of relapse in alcohol dependence.
    American family physician, 1999, Apr-01, Volume: 59, Issue:7

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Behavior Therapy; Disulfiram; Family; Humans; Naltrexone; Narcotic Antagonists; Recurrence; Self-Help Groups; Taurine

1999
Medical allies against alcoholism.
    Health news (Waltham, Mass.), 1999, Jun-25, Volume: 5, Issue:8

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Humans; Naltrexone; Taurine

1999
Occurrence and management of depression in the context of naltrexone treatment of alcoholism.
    The American journal of psychiatry, 1999, Volume: 156, Issue:8

    Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Comorbidity; Depressive Disorder; Diagnosis, Dual (Psychiatry); Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluoxetine; Humans; Middle Aged; Naltrexone; Narcotic Antagonists; Selective Serotonin Reuptake Inhibitors; Taurine

1999
Acamprosate, but not naltrexone, inhibits conditioned abstinence behaviour associated with repeated ethanol administration and exposure to a plus-maze.
    Psychopharmacology, 2000, Volume: 147, Issue:4

    Topics: Acamprosate; Alcohol Deterrents; Animals; Anxiety; Central Nervous System Depressants; Ethanol; Exploratory Behavior; Male; Mice; Naltrexone; Substance Withdrawal Syndrome; Taurine

2000
Pharmacological validation of a new animal model of alcoholism.
    Journal of neural transmission (Vienna, Austria : 1996), 2000, Volume: 107, Issue:6

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Behavior, Animal; Disease Models, Animal; Naltrexone; Narcotic Antagonists; Rats; Reproducibility of Results; Secondary Prevention; Self Administration; Substance Withdrawal Syndrome; Taurine

2000
Can this pill stop you from hitting the bottle?
    Newsweek, 2001, Feb-12, Volume: 137, Issue:7

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Counseling; Humans; Motivation; Naltrexone; Narcotic Antagonists; Taurine; United States

2001
Effect of acamprosate and naltrexone, alone or in combination, on ethanol consumption.
    Alcohol (Fayetteville, N.Y.), 2001, Volume: 23, Issue:2

    Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Animals; Male; Naltrexone; Narcotic Antagonists; Rats; Rats, Wistar; Taurine

2001
Combined behavioral and pharmacologic treatments of alcoholism.
    American clinical laboratory, 2001, Volume: 20, Issue:6

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Behavior Therapy; Combined Modality Therapy; Humans; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Taurine

2001
Does the alcoholic's remedy come in a pill?
    Behavioral healthcare tomorrow, 2001, Volume: 10, Issue:4

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Excitatory Amino Acid Antagonists; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Ondansetron; Patient Compliance; Serotonin Antagonists; Social Support; Taurine; United States

2001
Addiction medicine for the primary care physician.
    The Journal of the Oklahoma State Medical Association, 2001, Volume: 94, Issue:11

    Topics: Acamprosate; Alcohol Deterrents; Alcoholics Anonymous; Alcoholism; Antidepressive Agents, Tricyclic; Disulfiram; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Primary Health Care; Recurrence; Risk Factors; Severity of Illness Index; Substance-Related Disorders; Taurine; Treatment Outcome

2001
Drug treatments for alcoholism.
    The Harvard mental health letter, 2002, Volume: 18, Issue:10

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Humans; Naltrexone; Substance Withdrawal Syndrome; Taurine

2002
Effects of naltrexone alone and in combination with acamprosate on the alcohol deprivation effect in rats.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2003, Volume: 28, Issue:8

    Topics: Acamprosate; Alcohol Drinking; Animals; Behavior, Addictive; Conditioning, Operant; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ethanol; Male; Naltrexone; Rats; Rats, Wistar; Taurine; Temperance

2003
Physicians' opinions about medications to treat alcoholism.
    Addiction (Abingdon, England), 2003, Volume: 98, Issue:5

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Attitude of Health Personnel; Clinical Competence; Disulfiram; Health Care Surveys; Humans; Naltrexone; Narcotic Antagonists; Taurine; Treatment Outcome

2003
New pharmacotherapies for alcohol dependence: are they being used and what do they cost?
    The Medical journal of Australia, 2003, Aug-18, Volume: 179, Issue:4

    Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Australia; Humans; Naltrexone; Taurine; Treatment Refusal

2003
Effect of the combination of naltrexone and acamprosate on alcohol intake in mice.
    Psychiatry and clinical neurosciences, 2004, Volume: 58, Issue:1

    Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Animals; Dose-Response Relationship, Drug; Drug Therapy, Combination; Male; Mice; Mice, Inbred C57BL; Naltrexone; Narcotic Antagonists; Taurine

2004
The NMDA receptor channel blocker memantine and opioid receptor antagonist naltrexone inhibit the saccharin deprivation effect in rats.
    Behavioural pharmacology, 2004, Volume: 15, Issue:4

    Topics: Acamprosate; Animals; Choice Behavior; Ethanol; Male; Memantine; Naloxone; Naltrexone; Narcotic Antagonists; Rats; Rats, Wistar; Receptors, N-Methyl-D-Aspartate; Saccharin; Substance Withdrawal Syndrome; Sweetening Agents; Taurine

2004
The mosaic of addiction.
    The American journal of psychiatry, 2004, Volume: 161, Issue:10

    Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Behavior, Addictive; Disease Models, Animal; Endorphins; Ethanol; Euphoria; Humans; Naltrexone; Receptors, Dopamine D2; Receptors, Opioid; Secondary Prevention; Taurine

2004
Ask the doctor. I need to quit drinking, but don't think I can do it on my own. Can I use a drug like Antabuse even though I have heart disease?
    Harvard heart letter : from Harvard Medical School, 2004, Volume: 15, Issue:2

    Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Contraindications; Disulfiram; Heart Diseases; Humans; Naltrexone; Taurine

2004
Acamprosate campral for alcoholism.
    The Medical letter on drugs and therapeutics, 2005, Jan-03, Volume: 47, Issue:1199

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Diarrhea; Disulfiram; Drug Therapy, Combination; Humans; Naltrexone; Taurine

2005
[The pharmacologic treatment of the alcohol dependence].
    Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999), 2004, Volume: 26 Suppl 1

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Humans; Naltrexone; Narcotic Antagonists; Taurine

2004
A neuroendocrinological hypothesis on gender effects of naltrexone in relapse prevention treatment.
    Pharmacopsychiatry, 2005, Volume: 38, Issue:4

    Topics: Acamprosate; Adult; Alcoholism; Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Neurosecretory Systems; Secondary Prevention; Sex Characteristics; Taurine

2005
Challenges and opportunities for medications development in alcoholism: an international perspective on collaborations between academia and industry.
    Alcoholism, clinical and experimental research, 2005, Volume: 29, Issue:8

    Topics: Academies and Institutes; Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Cooperative Behavior; Cross-Cultural Comparison; Disulfiram; Drug Approval; Drug Industry; Drugs, Investigational; Evidence-Based Medicine; Humans; Interprofessional Relations; Naltrexone; Outcome Assessment, Health Care; Randomized Controlled Trials as Topic; Taurine

2005
Drug treatment for alcoholism today.
    The Harvard mental health letter, 2005, Volume: 22, Issue:1

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Antidepressive Agents; Disulfiram; Fructose; Humans; Naltrexone; Substance Withdrawal Syndrome; Taurine; Topiramate

2005
Choosing pharmacotherapies for the COMBINE Study--process and procedures: an investigational approach to combination pharmacotherapy for the treatment of alcohol dependence.
    Journal of studies on alcohol. Supplement, 2005, Issue:15

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Behavior Therapy; Clinical Trials as Topic; Combined Modality Therapy; Drug Administration Schedule; Humans; Naltrexone; Narcotic Antagonists; Research Design; Taurine; Treatment Outcome

2005
The COMBINE SAFTEE: a structured instrument for collecting adverse events adapted for clinical studies in the alcoholism field.
    Journal of studies on alcohol. Supplement, 2005, Issue:15

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Clinical Trials as Topic; Drug Monitoring; Drug-Related Side Effects and Adverse Reactions; Guidelines as Topic; Health Personnel; Humans; Naltrexone; Narcotic Antagonists; Observer Variation; Surveys and Questionnaires; Taurine; Terminology as Topic

2005
New alcohol abuse drugs emerging. Anti-craving meds are finally here to treat alcohol dependence, recognized as a disease of the brain.
    Health news (Waltham, Mass.), 2005, Volume: 11, Issue:12

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Humans; Naltrexone; Taurine

2005
Use of pharmacotherapies for the management of addictive behaviours in Australian clinical practice.
    Addictive behaviors, 2006, Volume: 31, Issue:11

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Australia; Bupropion; Dopamine Uptake Inhibitors; Female; Health Care Surveys; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Nicotine; Substance-Related Disorders; Taurine; Tobacco Use Disorder

2006
The BRENDA model: integrating psychosocial treatment and pharmacotherapy for the treatment of alcohol use disorders.
    Journal of psychiatric practice, 2006, Volume: 12, Issue:2

    Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Attitude to Health; Disulfiram; Humans; Male; Naltrexone; Narcotic Antagonists; Patient Compliance; Psychological Theory; Psychology; Psychotherapy; Taurine

2006
Schedule-induced alcohol drinking: non-selective effects of acamprosate and naltrexone.
    Addiction biology, 2006, Volume: 11, Issue:1

    Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Animals; Appetitive Behavior; Dose-Response Relationship, Drug; Drinking; Hunger; Injections, Intraperitoneal; Male; Mice; Mice, Inbred Strains; Naltrexone; Reinforcement Schedule; Taurine; Thirst

2006
[Maintaining abstinence after alcohol detoxification].
    La Revue du praticien, 2006, May-31, Volume: 56, Issue:10

    Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Ambulatory Care; Behavior Therapy; Clinical Protocols; Cognitive Behavioral Therapy; Disulfiram; Follow-Up Studies; Humans; Naltrexone; Patient Care Planning; Psychoanalytic Therapy; Psychotherapy, Group; Psychotropic Drugs; Social Support; Taurine; Temperance

2006
Extended-release intramuscular naltrexone: a viewpoint by Henry R Kranzler.
    Drugs, 2006, Volume: 66, Issue:13

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Delayed-Action Preparations; Disulfiram; Humans; Injections, Intramuscular; Naltrexone; Narcotic Antagonists; Taurine

2006
Which treatment for alcohol dependence: naltrexone, acamprosate and/or behavioural intervention?
    Expert opinion on pharmacotherapy, 2006, Volume: 7, Issue:15

    Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Behavior Therapy; Drug Therapy, Combination; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Taurine; Treatment Outcome

2006
[Drugs against alcohol abuse].
    Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2006, Dec-14, Volume: 126, Issue:24

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Drug Evaluation; Humans; Naltrexone; Narcotic Antagonists; Taurine; Treatment Outcome

2006
Alcohol dependence and pharmacologic treatment. Introduction.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2007, Mar-01, Volume: 64, Issue:5 Suppl 3

    Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Disulfiram; Humans; Naltrexone; Taurine; United States

2007
Schizophrenia and co-occurring substance use disorder.
    The American journal of psychiatry, 2007, Volume: 164, Issue:3

    Topics: Acamprosate; Adult; Alcohol-Related Disorders; Antipsychotic Agents; Comorbidity; Diagnosis, Dual (Psychiatry); Disulfiram; Humans; Ill-Housed Persons; Male; Naltrexone; Schizophrenia; Substance-Related Disorders; Taurine

2007
Evidence for the role of dopamine D3 receptors in oral operant alcohol self-administration and reinstatement of alcohol-seeking behavior in mice.
    Addiction biology, 2007, Volume: 12, Issue:1

    Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Animals; Conditioning, Operant; Dose-Response Relationship, Drug; Injections, Intraperitoneal; Male; Mice; Mice, Inbred C57BL; Naltrexone; Nitriles; Receptors, Dopamine D3; Taurine; Tetrahydroisoquinolines

2007
Cloninger's typology and treatment outcome in alcohol-dependent subjects during pharmacotherapy with naltrexone.
    Addiction biology, 2008, Volume: 13, Issue:1

    Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Combined Modality Therapy; Double-Blind Method; Female; Follow-Up Studies; Genetic Predisposition to Disease; Germany; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Patient Compliance; Psychotherapy; Randomized Controlled Trials as Topic; Recurrence; Spain; Taurine; Treatment Outcome

2008
New therapies for alcohol dependence open options for office-based treatment.
    JAMA, 2007, Dec-05, Volume: 298, Issue:21

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Behavior Therapy; Disulfiram; Family Practice; Fructose; Humans; Naltrexone; Taurine; Topiramate

2007
A microdialysis study of extracellular levels of acamprosate and naltrexone in the rat brain following acute and repeated administration.
    Addiction biology, 2008, Volume: 13, Issue:1

    Topics: Acamprosate; Alcohol Deterrents; Animals; Biological Availability; Dose-Response Relationship, Drug; Drug Administration Schedule; Extracellular Fluid; Frontal Lobe; Injections, Intraperitoneal; Male; Metabolic Clearance Rate; Microdialysis; Naltrexone; Rats; Rats, Long-Evans; Taurine

2008
From the neurobiologic basis of alcohol dependency to pharmacologic treatment strategies: bridging the knowledge gap.
    Southern medical journal, 2008, Volume: 101, Issue:2

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Combined Modality Therapy; Ethanol; Humans; Naltrexone; Narcotic Antagonists; Psychotherapy; Receptors, Dopamine; Receptors, GABA; Receptors, Opioid; Taurine

2008
Effects of naltrexone and acamprosate on alcohol-induced NGFI-A expression in mouse brain.
    Neurochemical research, 2008, Volume: 33, Issue:10

    Topics: Acamprosate; Amygdala; Animals; Brain; Early Growth Response Protein 1; Ethanol; Male; Mice; Naltrexone; Taurine

2008
Intermittent access to 20% ethanol induces high ethanol consumption in Long-Evans and Wistar rats.
    Alcoholism, clinical and experimental research, 2008, Volume: 32, Issue:10

    Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Animals; Ethanol; Male; Models, Animal; Naltrexone; Narcotic Antagonists; Rats; Rats, Long-Evans; Rats, Wistar; Taurine; Time Factors

2008
[Pharmacotherapy of alcohol dependence].
    MMW Fortschritte der Medizin, 2008, May-19, Volume: 150 Suppl 2

    Topics: Acamprosate; Adrenergic beta-Antagonists; Alcohol Deterrents; Alcoholism; Ambulatory Care; Anticonvulsants; Benzodiazepines; Chlormethiazole; Ethanol; Family Practice; Humans; Naltrexone; Patient Admission; Secondary Prevention; Substance Withdrawal Syndrome; Taurine

2008
Preserved DNA from past clinical trials yields new information about a subtype of alcoholism.
    Current psychiatry reports, 2008, Volume: 10, Issue:5

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Alleles; Combined Modality Therapy; Drug Therapy, Combination; Genetic Carrier Screening; Humans; Naltrexone; Narcotic Antagonists; Polymorphism, Single Nucleotide; Prognosis; Psychotherapy; Randomized Controlled Trials as Topic; Receptors, Opioid, mu; Taurine; Treatment Outcome

2008
Alcohol and opioid dependence medications: prescription trends, overall and by physician specialty.
    Drug and alcohol dependence, 2009, Jan-01, Volume: 99, Issue:1-3

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Buprenorphine; Delayed-Action Preparations; Disulfiram; Drug Costs; Drug Prescriptions; Drug Therapy, Combination; Drug Utilization; Humans; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Osteopathic Medicine; Physicians; Physicians, Family; Psychiatry; Taurine; United States

2009
Acamprosate and naltrexone treatment effects on ethanol and sucrose seeking and intake in ethanol-dependent and nondependent rats.
    Psychopharmacology, 2009, Volume: 204, Issue:2

    Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Animals; Body Weight; Conditioning, Operant; Data Interpretation, Statistical; Male; Naltrexone; Rats; Rats, Long-Evans; Sucrose; Taste; Taurine

2009
Expectancy in double-blind placebo-controlled trials: an example from alcohol dependence.
    Psychotherapy and psychosomatics, 2009, Volume: 78, Issue:3

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Double-Blind Method; Humans; Naltrexone; Narcotic Antagonists; Patient Compliance; Psychotherapy; Taurine; Treatment Outcome

2009
Treatment of alcohol dependence.
    The Ceylon medical journal, 2009, Volume: 54, Issue:2

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Fructose; Humans; Naltrexone; Narcotic Antagonists; Neuroprotective Agents; Taurine; Topiramate; Vitamins

2009
Alcohol dependence: after the withdrawal phase. Long-term abstinence: better health and psychosocial status. Psychosocial support for a chronic disorder. Some drugs are useful adjuncts to medical support.
    Prescrire international, 2009, Volume: 18, Issue:103

    Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcohol-Related Disorders; Alcoholics; Alcoholism; Anticonvulsants; Baclofen; Clinical Trials as Topic; Combined Modality Therapy; Disulfiram; France; Fructose; Health Status; Humans; Naltrexone; Psychotherapy; Randomized Controlled Trials as Topic; Secondary Prevention; Self-Help Groups; Social Support; Taurine; Temperance; Topiramate; Treatment Outcome

2009
Naltrexone and combined behavioral intervention effects on trajectories of drinking in the COMBINE study.
    Drug and alcohol dependence, 2010, Mar-01, Volume: 107, Issue:2-3

    Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Behavior Therapy; Combined Modality Therapy; Drug Therapy, Combination; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Odds Ratio; Randomized Controlled Trials as Topic; Taurine; Treatment Outcome; United States

2010
The adoption of alcohol pharmacotherapies in the Clinical Trials Network: the influence of research network participation.
    Journal of substance abuse treatment, 2010, Volume: 38, Issue:3

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Clinical Trials as Topic; Diffusion of Innovation; Follow-Up Studies; Health Services Research; Humans; Naltrexone; Nitrosamines; Organizational Culture; Organizational Innovation; Substance Abuse Treatment Centers; Taurine; United States

2010
Pharmacotherapies for alcoholism: the old and the new.
    CNS & neurological disorders drug targets, 2010, Volume: 9, Issue:1

    Topics: Acamprosate; Alcohol Deterrents; Alcohol-Induced Disorders, Nervous System; Alcoholism; Animals; Disease Models, Animal; Disulfiram; Drug Design; Humans; Naltrexone; Narcotic Antagonists; Neuropeptides; Neuropharmacology; Neurotransmitter Agents; Receptors, Neurotransmitter; Taurine

2010
Revisiting the cost-effectiveness of the COMBINE study for alcohol dependent patients: the patient perspective.
    Medical care, 2010, Volume: 48, Issue:4

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Behavior Therapy; Combined Modality Therapy; Cost-Benefit Analysis; Financing, Personal; Health Expenditures; Humans; Naltrexone; Patient Acceptance of Health Care; Prospective Studies; Randomized Controlled Trials as Topic; Taurine; United States

2010
Pharmacotherapy of alcohol use disorders in the Veterans Health Administration.
    Psychiatric services (Washington, D.C.), 2010, Volume: 61, Issue:4

    Topics: Acamprosate; Administration, Oral; Adult; Age Factors; Alcohol Deterrents; Alcoholism; Ambulatory Care; Comorbidity; Delayed-Action Preparations; Disulfiram; Drug Therapy, Combination; Drug Utilization; Female; Humans; Injections, Intramuscular; Male; Mental Disorders; Middle Aged; Naltrexone; Selective Serotonin Reuptake Inhibitors; Sex Factors; Substance Abuse Treatment Centers; Taurine; United States; Veterans

2010
The effect of alcohol treatment on social costs of alcohol dependence: results from the COMBINE study.
    Medical care, 2010, Volume: 48, Issue:5

    Topics: Acamprosate; Accidents, Traffic; Alcohol Deterrents; Alcohol-Related Disorders; Behavior Therapy; Costs and Cost Analysis; Crime; Health Services; Humans; Naltrexone; Taurine

2010
Gender differences in alcohol treatment: an analysis of outcome from the COMBINE study.
    Alcoholism, clinical and experimental research, 2010, Volume: 34, Issue:10

    Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Behavior Therapy; Combined Modality Therapy; Drug Therapy, Combination; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Sex Characteristics; Taurine; Treatment Outcome

2010
Percentage of subjects with no heavy drinking days: evaluation as an efficacy endpoint for alcohol clinical trials.
    Alcoholism, clinical and experimental research, 2010, Volume: 34, Issue:12

    Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Female; Fructose; Humans; Male; Naltrexone; Randomized Controlled Trials as Topic; Taurine; Temperance; Time Factors; Topiramate; Treatment Outcome

2010
Comparison of healthcare utilization among patients treated with alcoholism medications.
    The American journal of managed care, 2010, Volume: 16, Issue:12

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Delayed-Action Preparations; Disulfiram; Female; Health Services; Health Status Indicators; Humans; Inpatients; Insurance Claim Review; Male; Middle Aged; Naltrexone; Narcotics; Propensity Score; Retrospective Studies; Taurine; United States

2010
Using medication-assisted treatment for substance use disorders: evidence of barriers and facilitators of implementation.
    Addictive behaviors, 2011, Volume: 36, Issue:6

    Topics: Acamprosate; Alcohol Deterrents; Buprenorphine; Disulfiram; Humans; Naltrexone; Narcotic Antagonists; Patient Education as Topic; Substance Abuse Treatment Centers; Substance-Related Disorders; Taurine; United States

2011
Alcohol dependence treatments: comprehensive healthcare costs, utilization outcomes, and pharmacotherapy persistence.
    The American journal of managed care, 2011, Volume: 17 Suppl 8

    Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Chi-Square Distribution; Databases, Factual; Disulfiram; Female; Health Care Costs; Health Services; Humans; Male; Naltrexone; Narcotic Antagonists; Propensity Score; Retrospective Studies; Statistics as Topic; Statistics, Nonparametric; Taurine; Treatment Outcome; United States

2011
Pharmacogenetics of alcoholism: a clinical neuroscience perspective.
    Pharmacogenomics, 2012, Volume: 13, Issue:2

    Topics: Acamprosate; Alcoholism; Alleles; Disulfiram; Genetic Markers; Humans; Naltrexone; Narcotic Antagonists; Polymorphism, Single Nucleotide; Precision Medicine; Receptors, Opioid, mu; Serotonin Plasma Membrane Transport Proteins; Taurine

2012
Pharmacotherapy for adolescent alcohol use disorder.
    CNS drugs, 2012, Jul-01, Volume: 26, Issue:7

    Topics: Acamprosate; Adolescent; Alcohol-Related Disorders; Antidepressive Agents; Attention Deficit Disorder with Hyperactivity; Benzodiazepines; Central Nervous System Stimulants; Comorbidity; Diagnostic and Statistical Manual of Mental Disorders; Disulfiram; Humans; Naltrexone; Substance Withdrawal Syndrome; Substance-Related Disorders; Taurine

2012
Cocaine reverses the naltrexone-induced reduction in operant ethanol self-administration: the effects on immediate-early gene expression in the rat prefrontal cortex.
    Neuropharmacology, 2012, Volume: 63, Issue:6

    Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Animals; Carrier Proteins; Cocaine; Conditioning, Operant; Cyclooxygenase 2; Dose-Response Relationship, Drug; Gene Expression; Genes, fos; Genes, Immediate-Early; Homer Scaffolding Proteins; Male; Motor Activity; Naltrexone; Narcotic Antagonists; Prefrontal Cortex; Rats; Rats, Wistar; Real-Time Polymerase Chain Reaction; Self Administration; Taurine

2012
Pharmacotherapy for alcohol dependence: perceived treatment barriers and action strategies among Veterans Health Administration service providers.
    Psychological services, 2013, Volume: 10, Issue:4

    Topics: Acamprosate; Adult; Aged; Alcohol Deterrents; Alcoholism; Attitude of Health Personnel; Disulfiram; Drug Utilization; Female; Formularies as Topic; Health Care Surveys; Health Knowledge, Attitudes, Practice; Health Services Accessibility; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Patient Preference; Practice Guidelines as Topic; Practice Patterns, Physicians'; Qualitative Research; Taurine; United States; United States Department of Veterans Affairs; Veterans Health

2013
Temporal patterns of adherence to medications and behavioral treatment and their relationship to patient characteristics and treatment response.
    Addictive behaviors, 2013, Volume: 38, Issue:5

    Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Behavior Therapy; Combined Modality Therapy; Female; Humans; Male; Medication Adherence; Naltrexone; Patient Compliance; Patient Satisfaction; Taurine; Time Factors; Treatment Outcome

2013
[Drug therapy supports reduction of alcohol consumption].
    Medizinische Monatsschrift fur Pharmazeuten, 2014, Volume: 37, Issue:9

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Humans; Meta-Analysis as Topic; Naltrexone; Taurine

2014
Nicotine-induced locomotor sensitization: pharmacological analyses with candidate smoking cessation aids.
    Addiction biology, 2016, Volume: 21, Issue:2

    Topics: Acamprosate; Analysis of Variance; Animals; Antidiuretic Hormone Receptor Antagonists; Bupropion; Dose-Response Relationship, Drug; Fructose; Indoles; Male; Motor Activity; Naltrexone; Nicotine; Nicotinic Agonists; Pyrrolidines; Rats, Wistar; Taurine; Tobacco Use Cessation Devices; Topiramate

2016
Predictors of abstinence from heavy drinking during treatment in COMBINE and external validation in PREDICT.
    Alcoholism, clinical and experimental research, 2014, Volume: 38, Issue:10

    Topics: Acamprosate; Age Factors; Alcohol Abstinence; Alcohol Deterrents; Alcohol Drinking; Behavior Therapy; Combined Modality Therapy; Controlled Clinical Trials as Topic; Decision Trees; gamma-Glutamyltransferase; Germany; Goals; Humans; Logistic Models; Middle Aged; Naltrexone; Predictive Value of Tests; Randomized Controlled Trials as Topic; Reproducibility of Results; Taurine; Time Factors; Treatment Outcome; United States

2014
Comparison of dehydroepiandrosterone (DHEA) and pregnanolone with existing pharmacotherapies for alcohol abuse on ethanol- and food-maintained responding in male rats.
    Alcohol (Fayetteville, N.Y.), 2015, Volume: 49, Issue:2

    Topics: Acamprosate; Alcohol Drinking; Alcoholism; Animals; Dehydroepiandrosterone; Dose-Response Relationship, Drug; Eating; Ethanol; Male; Naltrexone; Pregnanolone; Rats; Rats, Long-Evans; Self Administration; Taurine

2015
[Acamprosate and naltrexone: similar efficacy for relapse].
    Revue medicale suisse, 2014, Dec-17, Volume: 10, Issue:455

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Humans; Naltrexone; Narcotic Antagonists; Recurrence; Taurine

2014
Medicaid coverage of medications to treat alcohol and opioid dependence.
    Journal of substance abuse treatment, 2015, Volume: 55

    Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Buprenorphine, Naloxone Drug Combination; Humans; Insurance Coverage; Medicaid; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Taurine; United States

2015
Association between a brief alcohol craving measure and drinking in the following week.
    Addiction (Abingdon, England), 2016, Volume: 111, Issue:6

    Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Cognitive Behavioral Therapy; Craving; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Odds Ratio; Randomized Controlled Trials as Topic; Taurine; United States

2016
Access to Addiction Pharmacotherapy in Private Health Plans.
    Journal of substance abuse treatment, 2016, Volume: 66

    Topics: Acamprosate; Buprenorphine; Cost Sharing; Evidence-Based Practice; Formularies as Topic; Health Services Accessibility; Humans; Insurance, Health; Naltrexone; Substance-Related Disorders; Surveys and Questionnaires; Taurine; United States

2016
National trends in alcohol pharmacotherapy: Findings from an Australian claims database.
    Drug and alcohol dependence, 2016, Sep-01, Volume: 166

    Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Australia; Drug Administration Schedule; Female; Guideline Adherence; Humans; Insurance Claim Review; Male; Naltrexone; Patient Compliance; Retrospective Studies; Taurine; Temperance

2016
Pharmacotherapy for Adults with Alcohol Use Disorder.
    American family physician, 2016, Jul-15, Volume: 94, Issue:2

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Humans; Naltrexone; Narcotic Antagonists; Taurine

2016
Marketing Status and Perceived Efficacy of Drugs for Supporting Abstinence and Reducing Alcohol Intake in Alcohol Use Disorders: A Survey among European Federation of Addiction Societies in Europe.
    European addiction research, 2016, Volume: 22, Issue:6

    Topics: Acamprosate; Alcohol Abstinence; Alcohol Deterrents; Alcohol-Related Disorders; Disulfiram; Europe; Humans; Marketing; Naltrexone; Narcotic Antagonists; Perception; Practice Guidelines as Topic; Societies, Medical; Surveys and Questionnaires; Taurine; Treatment Outcome

2016
Multifaceted academic detailing program to increase pharmacotherapy for alcohol use disorder: interrupted time series evaluation of effectiveness.
    Addiction science & clinical practice, 2016, 09-15, Volume: 11, Issue:1

    Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol-Related Disorders; Disulfiram; Female; Fructose; Humans; Male; Middle Aged; Naltrexone; Patient Compliance; Taurine; Topiramate; United States; United States Department of Veterans Affairs; Veterans; Young Adult

2016
A Naturalistic Evaluation of Extended-Release Naltrexone in Clinical Practice in Missouri.
    Journal of substance abuse treatment, 2016, Volume: 70

    Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol-Related Disorders; Delayed-Action Preparations; Female; Humans; Male; Middle Aged; Missouri; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Outcome Assessment, Health Care; Psychotherapy; Taurine

2016
Cannabis use during treatment for alcohol use disorders predicts alcohol treatment outcomes.
    Addiction (Abingdon, England), 2017, Volume: 112, Issue:4

    Topics: Acamprosate; Adult; Alcohol Abstinence; Alcohol Deterrents; Alcoholism; Behavior Therapy; Combined Modality Therapy; Comorbidity; Drug Therapy, Combination; Female; Humans; Male; Marijuana Use; Middle Aged; Naltrexone; Narcotic Antagonists; Prognosis; Randomized Controlled Trials as Topic; Taurine; Treatment Outcome

2017
Socioeconomic and geographic disparities in access to pharmacotherapy for alcohol dependence.
    Journal of substance abuse treatment, 2017, Volume: 74

    Topics: Acamprosate; Adolescent; Adult; Aged; Aged, 80 and over; Alcohol Deterrents; Alcoholism; Australia; Drug Prescriptions; Female; Health Services Accessibility; Healthcare Disparities; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Retrospective Studies; Social Class; Taurine; Vulnerable Populations; Young Adult

2017
Barriers to and facilitators of pharmacotherapy for alcohol use disorder in VA residential treatment programs.
    Journal of substance abuse treatment, 2017, Volume: 77

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Female; Humans; Interviews as Topic; Male; Naltrexone; Residential Treatment; Taurine; United States; United States Department of Veterans Affairs; Veterans

2017
First-line medications for alcohol use disorders among public drug plan beneficiaries in Ontario.
    Canadian family physician Medecin de famille canadien, 2017, Volume: 63, Issue:5

    Topics: Acamprosate; Adult; Aged; Alcohol Deterrents; Alcoholism; Female; Humans; Insurance, Pharmaceutical Services; Male; Middle Aged; Naltrexone; Ontario; Population Surveillance; Retrospective Studies; Single-Payer System; Taurine; Young Adult

2017
Who achieves low risk drinking during alcohol treatment? An analysis of patients in three alcohol clinical trials.
    Addiction (Abingdon, England), 2017, Volume: 112, Issue:12

    Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Behavior Therapy; Combined Modality Therapy; Drinking Behavior; Female; Humans; Male; Naltrexone; Risk; Taurine; Treatment Outcome; United Kingdom; United States

2017
More Treatments on Deck for Alcohol Use Disorder.
    JAMA, 2017, Jun-13, Volume: 317, Issue:22

    Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Amines; Baclofen; Cyclohexanecarboxylic Acids; Cytidine Diphosphate Choline; Disulfiram; Drug Repositioning; Fructose; Gabapentin; gamma-Aminobutyric Acid; Humans; Mifepristone; Naltrexone; National Institute on Alcohol Abuse and Alcoholism (U.S.); Off-Label Use; Patient Acceptance of Health Care; Taurine; Topiramate; United States; Varenicline

2017
High Drinking in the Dark (HDID) mice are sensitive to the effects of some clinically relevant drugs to reduce binge-like drinking.
    Pharmacology, biochemistry, and behavior, 2017, Volume: 160

    Topics: Acamprosate; Animals; Baclofen; Binge Drinking; Darkness; Disease Models, Animal; Ethanol; Female; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Naltrexone; Taurine

2017
Commentary on Palpacuer et al. (2018): Do small effects on total alcohol consumption translate into clinical practice?
    Addiction (Abingdon, England), 2018, Volume: 113, Issue:2

    Topics: Acamprosate; Alcohol Drinking; Alcoholism; Baclofen; Humans; Naltrexone; Narcotic Antagonists; Network Meta-Analysis; Topiramate

2018
Evaluation of alcohol use disorders pharmacotherapies in a new preclinical model of binge drinking.
    Neuropharmacology, 2018, 09-15, Volume: 140

    Topics: Acamprosate; Animals; Baclofen; Binge Drinking; Conditioning, Operant; Disease Models, Animal; Dose-Response Relationship, Drug; Ethanol; Extinction, Psychological; Hydroxybutyrates; Male; Motivation; Naltrexone; Rats; Self Administration

2018
Medications for Alcohol and Opioid Use Disorders and Risk of Suicidal Behavior, Accidental Overdoses, and Crime.
    The American journal of psychiatry, 2018, 10-01, Volume: 175, Issue:10

    Topics: Acamprosate; Adult; Aged; Alcohol Deterrents; Alcoholism; Buprenorphine; Cohort Studies; Crime; Drug Overdose; Female; Follow-Up Studies; Humans; Male; Methadone; Middle Aged; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Risk Factors; Suicidal Ideation; Young Adult

2018
Risk of hospitalisation and death related to baclofen for alcohol use disorders: Comparison with nalmefene, acamprosate, and naltrexone in a cohort study of 165 334 patients between 2009 and 2015 in France.
    Pharmacoepidemiology and drug safety, 2018, Volume: 27, Issue:11

    Topics: Acamprosate; Administrative Claims, Healthcare; Adult; Aged; Alcohol Deterrents; Alcoholism; Baclofen; Databases, Factual; Dose-Response Relationship, Drug; Female; Follow-Up Studies; France; Hospitalization; Humans; Male; Middle Aged; Naltrexone; Off-Label Use; Risk Assessment; Socioeconomic Factors

2018
Cost-Effectiveness Analysis of Genotype-Guided Treatment Allocation in Patients with Alcohol Use Disorders Using Naltrexone or Acamprosate, Using a Modeling Approach.
    European addiction research, 2018, Volume: 24, Issue:5

    Topics: Acamprosate; Alcoholism; Alleles; Computer Simulation; Cost-Benefit Analysis; Genotype; Health Care Costs; Humans; Markov Chains; Models, Statistical; Naltrexone; Pharmacogenetics; Quality-Adjusted Life Years; Receptors, Opioid, mu; Treatment Outcome

2018
Use of drugs for alcohol use disorder in Norway 2004–16.
    Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2018, 11-13, Volume: 138, Issue:18

    Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol-Related Disorders; Disulfiram; Drug Prescriptions; Drug Utilization; Female; Humans; Male; Middle Aged; Naltrexone; Norway; Registries

2018
Prescription Drug and Alcohol Use Disorders: Alcohol Use Disorder.
    FP essentials, 2019, Volume: 478

    Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Disulfiram; Humans; Naltrexone

2019
Very Low Frequency of Drug Therapy of Alcohol Dependence in Germany - Analysis of Data of A Statutory Health Insurance.
    Pharmacopsychiatry, 2020, Volume: 53, Issue:1

    Topics: Acamprosate; Adult; Aged; Alcohol Deterrents; Alcoholism; Drug Utilization; Female; Germany; Humans; Male; Middle Aged; Naltrexone; Practice Patterns, Physicians'; Specialization

2020
Adherence Across FDA-Approved Medications for Alcohol Use Disorder in a Veterans Administration Population.
    Journal of studies on alcohol and drugs, 2019, Volume: 80, Issue:5

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Female; Humans; Male; Medication Adherence; Middle Aged; Naltrexone; Retrospective Studies; United States; United States Department of Veterans Affairs; United States Food and Drug Administration; Veterans

2019
Predictors of initiation of and retention on medications for alcohol use disorder among people living with and without HIV.
    Journal of substance abuse treatment, 2020, Volume: 109

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Cohort Studies; Female; HIV Infections; Humans; Male; Middle Aged; Naltrexone; Prevalence; Veterans

2020
A rapid access to addiction medicine clinic facilitates treatment of substance use disorder and reduces substance use.
    Substance abuse treatment, prevention, and policy, 2020, 01-13, Volume: 15, Issue:1

    Topics: Acamprosate; Addiction Medicine; Adult; Aged; Alcohol Deterrents; Alcoholism; Buprenorphine; Emergency Service, Hospital; Female; Gabapentin; Humans; Male; Middle Aged; Naltrexone; Ontario; Opioid-Related Disorders; Patient Acceptance of Health Care; Primary Health Care; Referral and Consultation; Socioeconomic Factors; Substance Abuse Treatment Centers; Substance-Related Disorders; Time Factors; Young Adult

2020
A Bayesian approach to discrete multiple outcome network meta-analysis.
    PloS one, 2020, Volume: 15, Issue:4

    Topics: Acamprosate; Alcoholism; Algorithms; Bayes Theorem; Humans; Monte Carlo Method; Naltrexone; Network Meta-Analysis; Safety

2020
The Persistent Challenge of Developing Addiction Pharmacotherapies.
    Cold Spring Harbor perspectives in medicine, 2021, 11-01, Volume: 11, Issue:11

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Bupropion; Central Nervous System Stimulants; Cocaine-Related Disorders; Drug Therapy; Humans; Naltrexone; Narcotic Antagonists; Nicotinic Agonists; Smoking Cessation Agents; Substance-Related Disorders; Varenicline

2021
Predictive factors of long-term follow-up in treatment of Korean alcoholics with naltrexone or acamprosate.
    International clinical psychopharmacology, 2020, Volume: 35, Issue:6

    Topics: Acamprosate; Adult; Alcoholics; Alcoholism; Female; Follow-Up Studies; Humans; Male; Middle Aged; Naltrexone

2020
Cost-effectiveness of alcohol use treatments in patients with alcohol-related cirrhosis.
    Journal of hepatology, 2021, Volume: 74, Issue:6

    Topics: Acamprosate; Aged; Alcohol Deterrents; Alcoholism; Cohort Studies; Cost-Benefit Analysis; Female; Health Care Costs; Humans; Liver Cirrhosis, Alcoholic; Male; Middle Aged; Naltrexone; Quality-Adjusted Life Years; Treatment Outcome

2021
Real-world effectiveness of pharmacological treatments of alcohol use disorders in a Swedish nation-wide cohort of 125 556 patients.
    Addiction (Abingdon, England), 2021, Volume: 116, Issue:8

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Cohort Studies; Female; Humans; Male; Naltrexone; Sweden

2021
Treatment of Alcohol Use Disorder.
    JAMA, 2021, 02-09, Volume: 325, Issue:6

    Topics: Acamprosate; Alcohol Deterrents; Alcoholics Anonymous; Alcoholism; Cognitive Behavioral Therapy; Disulfiram; Humans; Naltrexone

2021
Anticraving medication for moderate to severe alcohol use disorder.
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2021, 05-10, Volume: 193, Issue:19

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Craving; Female; Humans; Male; Naltrexone

2021
Trends in the Use of Naltrexone for Addiction Treatment among Alcohol Use Disorder Admissions in U.S. Substance Use Treatment Facilities.
    International journal of environmental research and public health, 2021, 08-23, Volume: 18, Issue:16

    Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Female; Humans; Middle Aged; Naltrexone; Substance-Related Disorders

2021
Examining a brief measure and observed cutoff scores to identify reward and relief drinking profiles: Psychometric properties and pharmacotherapy response.
    Drug and alcohol dependence, 2022, 03-01, Volume: 232

    Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Female; Humans; Male; Naltrexone; Psychometrics; Reward

2022
Monitoring alcohol-use-disorder medication compliance by LC-MS/MS determination of urinary ethyl glucuronide, acamprosate, naltrexone, and 6β-naltrexol using zirconia-based hybrid solid-phase extraction.
    Journal of pharmaceutical and biomedical analysis, 2022, Apr-01, Volume: 212

    Topics: Acamprosate; Alcoholism; Chromatography, High Pressure Liquid; Chromatography, Liquid; Glucuronates; Humans; Medication Adherence; Naltrexone; Solid Phase Extraction; Tandem Mass Spectrometry; Zirconium

2022
Impact of policy changes and drug shortages on acamprosate and naltrexone use in Ontario, Canada.
    Drug and alcohol dependence, 2023, 01-01, Volume: 242

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Female; Humans; Male; Naltrexone; Ontario; Taurine

2023
Medications for alcohol use disorder improve survival in patients with hazardous drinking and alcohol-associated cirrhosis.
    Hepatology communications, 2023, 04-01, Volume: 7, Issue:4

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Humans; Liver Cirrhosis; Liver Cirrhosis, Alcoholic; Naltrexone; Retrospective Studies

2023